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Mass Spectrometry-Based Approaches for Targeted Quantitative Proteomics in Biomarker 
Development 
 
Mary Joan Castillo, Ph.D. 
University of Connecticut, 2015 
 
 
The development of disease protein biomarkers and their use in clinical research have great 
applications in the diagnosis, prognosis, and treatment of complex diseases. Mass spectrometry 
methods for protein biomarker quantitation have recently gained importance in the early stages 
of the biomarker pipeline, but their application in the validation phase is limited by their low 
sample throughput. The technology of ultrathroughput mass spectrometry (uMS) transforms the 
intrinsic quantitation capability of MS analyte multiplexing to sample multiplexing. Herein, the 
novel MS-based bioanalytical platform utilized decoupled use of isotopic quantitation reference 
standard and non-isotopic mass coding reagents to enable one-experiment quantitation of a target 
protein biomarker candidate in multiple non-depleted serum samples. Screened repository of 
signal-enhancing peptidyl reagents enabled N-in-1 analyses for a cost-effective, high sample 
throughput strategy for protein biomarker validation applications. The signal enhancement and 
sample multiplexing capability of the derivatization technique were then further investigated 
within proteomic profiling and derived towards a global quantitative approach. 
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Chapter 1. Introduction 
 
1.1. The disease protein biomarker and the development pipeline 
 
A biomarker, derived from the term “biological marker”, is defined by the National 
Institutes of Health as “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention”.1,2 The World Health Organization further described biomarker as “any 
substance, structure, or process that can be measured in the body or its products and influence or 
predict the incidence of outcome or disease”.3As objective measureable characteristics of 
biological processes, any measured response - from blood pressure, pulse, basic blood chemistry 
through complex tissue and blood composition, can serve as biomarkers.  
 
Biomarkers have been mostly treated as surrogate endpoints (variables representing the 
clinical state of an organism) when they are well-characterized, clinically evaluated, and 
statistically validated. Despite the debates regarding the criteria for its utility, biomarker 
discovery and its eventual development are rooted in two important clinical aspects: relevance 
and validity. Ultimately, the candidate biomarker should both present clinically significant 
information and reliable characterization of the efficacy as a marker.1 Increased recent scientific 
efforts on the pursuit for effective biomarkers reflect their enormous potential to revolutionize 
diagnosis, prognosis, and personalized treatment of almost every disease. Integrated omics 
technologies and high-throughput methodologies have led to continually increasing studies on 
the discovery of putative biomarkers.4  
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Among the biological molecules that can qualify as biomarkers, proteins are most widely 
studied.4 Tissue leakage proteins are carried onto the bloodstream and are therefore secreted into 
other bodily fluids.  In the diseased state, pathological functions of human tissues and organs are 
affected and dysregulated. Proteins are highly dynamic and diverse molecules that greatly reflect 
the biological differences based on the extent of the disease. Changes in the proteins associated 
with the disease can include co/post-translational modification, cellular localization, interaction, 
and activity.5  
 
The biomarker pipeline, illustrated in Figure 1.1, commences with the discovery of 
putative biomarkers for a certain disease or condition. Upon further characterization and 
evaluation, increasing numbers of samples are analyzed for the verification and validation phases 
where more targeted methods are required. The long path from discovery to validation, in terms 
of cost and time, is comparable to a candidate drug development. The development of validated 
biomarkers that have already received Food and Drug Administration (FDA) approval such as 
human epididymis 4 (ovarian cancer), interleukin 1 receptor-like 1 protein (heart failure), and 
tryptase (mastocytosis) spanned from 8 to 20 years.1,4 
 
 
Figure 1.1. The protein biomarker pipeline. 
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1.2. Protein biomarker discovery from quantitative proteomic profiling 
 
1.2.1. Discovery of novel biomarkers 
 
  As increased scientific efforts have been spent to discovering novel biomarkers, potential 
protein biomarkers and their discovery rely on reliable determination of their quantitative 
changes in healthy and diseased samples. The progression of the disease signified by the changes 
in the protein requires accurate and precise quantitative measurements in biological samples. 
Typically, the non-targeted aspect of the discovery phase entails fold changes or up/down-
regulation results.6 Compared to high-abundant proteins in sera or plasma, many novel protein 
biomarkers have low concentration, usually in the low nanogram range. As such, in the initial 
stage of discovery, it is only practical to utilize tissue samples or other body fluids in close 
proximity or within the diseased organ of the individual. Despite being obtained from more 
invasive clinical sampling, the analysis enables determination of relevant proteins that are varied 
between control and diseased specimens.7 From these samples, sufficient limits of detection or 
quantitation are attained to produce a global quantitative profile for the identification of certain 
potential biomarkers that have significant changes.  
 
1.2.2. Mass spectrometry-based technologies for proteomic quantitation 
 
 Quantitative profiling of dissected tissue samples using mass spectrometry methods for 
biomarker discovery are based on sample libraries such as post-mortem formalin-fixed paraffin-
embedded (FFPE) tissues. Sectional analysis on differential protein expression can be performed, 
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as well as comparative studies among sections from the same tissue.8 Human proximal fluids are 
also ideal samples in examining variations in proteomic profiles for a specific disease. Analysis 
of gastric fluid, interstitial and peritoneal fluid, and urine9-12 had revealed distinct protein profiles 
and were examined for the discovery of novel biomarkers. Observable changes or occurrence of 
a protein isomer can also be indicative of a diseased state, as reported in the case of Alzheimer’s 
disease enzyme production.13 Moreover, recent reports have shown changes in post-translational 
modifications associated with dysregulated pathological functionalities and disease progress.14-16 
 
 Over the past years, mass spectrometry (MS)-based proteomic analyses have generated 
thousands of potential disease biomarkers. Following initial proteolytic digestion of proteins, the 
surrogate peptides are quantified, which signifies the basis of relative quantitation: a bottom-up 
approach (also known as shotgun proteomics). Methods in the quantitative proteomics toolbox, 
shown in Figure 1.2, including more recently developed techniques, are mainly classified as 
label-free and derivatization-based (under Common Technologies).  
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 Figure 1.2. Quantitative proteomic tools for discovering protein biomarkers (adapted 
from book chapter, “Quantitative Proteomics in Development of Protein Biomarkers” by Yao, et 
al in Proteomic and Metabolomic Approaches to Biomarker Discovery).5 
 
Label or derivatization-based methods have been continually explored recently. An 
important labeling method, the enzymatic 18O-labeling of peptides, is a simple and sensitive 
technique that incorporates two atoms of 18O at the peptide C-termini.17,18 Usually applied for 
comparative quantitation, protein digests are labeled through incubation with proteases in buffers 
made of H2
18O or H2
16O. The method is typically employed for the investigation of proteins of 
interest in diseased and control samples. As the control sample can be used as the master control 
for the analysis, the enzyme-catalyzed technique was further utilized for preparation of a global 
reference standard for biomarker discovery.19 Co- and post-translational modifications can also 
Quantitative Proteomic 
Profiling of Human 
Proteome Samples
Common Technologies
Enzymatic 18O-Labeling
Chemical Tagging of Stable 
Isotope Labels
Metabolic Labeling
Label-free
Protein Biomarker 
Discovery
Differentially-Expressed 
Proteins
Disease-Specific Protein 
Isomers
Abnormal Protein Activities
6 
 
be investigated from MS results of labeled proteotypic peptides.20,21 The labeling is both robust 
and inexpensive, without extensive cleanup and complex sample processing steps. Moreover, 
18O-water serves as the reagent and is added in large excess, providing rapid and efficient 
labeling mechanism. More recent application of this method involved 18O-labeling of biological 
samples such as plasma, sera, and microdissected tissue.19,22,23 
 
Discovery of potential biomarkers from biological samples imposes good sensitivity and 
accurate quantitation within a meaningful number of diseased and control samples, as clinical 
variability is an essential factor to consider.24 To improve accuracy and multiplexing of multiple 
samples, chemical tags with stable isotope labels are available to differentially code each sample, 
respectively. These reagents, which can be commercially purchased, provide simple and 
straightforward sample processing protocols. 
 
1.3. Protein biomarker validation 
  
1.3.1. Current high sample throughput methods 
 
Reliable detection and quantitation of candidate protein biomarkers are performed 
through bioanalytical platforms that have the capability to measure analytes in complex 
biological samples. In the discovery phase of biomarker development, the analysis requires 
multiplexed quantitation of multiple proteins in a small number of samples. Potential biomarkers 
are then subsequently identified, qualified, and verified before validation phase ensues. MS 
methods for multiplexed protein quantitation in complex biological samples have been essential 
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in the discovery phase of the biomarker pipeline.5,25 As candidate biomarkers advance through 
the validation phase, however, the mode of analysis should be transformed to facilitate increased 
number of samples wherein fewer analytes are quantified. The sample throughput bottleneck 
limits the current mass spectrometry methods in the validation phase of protein biomarker 
development. Typically during validation, the analysis requires high sample throughput targeted 
protein quantitation, where clinically significant number of biological samples can be processed.7 
 
Currently, the gold standard methods for the validation of protein biomarkers are 
conducted using immunograde antibodies and immunoassays such as enzyme-linked 
immunosorbent assay (ELISA).26 These techniques, however, are costly and lengthy to develop; 
they also involve production of a specific immunograde antibody for a candidate protein 
biomarker, making them non-flexible for other candidates.27 Usually in validation studies 
involving thousands of patient-control samples, less than ten protein candidates are analyzed. In 
addition, an immunoassay necessitates a single immunograde antibody for one candidate, 
making it even more expensive for verifying and validating those candidates without existing 
immunograde antibodies. 
 
 Clinical sampling for validation takes into account the accessibility and invasiveness of 
the patient sample collection. The samples of choice are blood and other easily sampled body 
fluids. At this point, candidate biomarkers resulting from tissue or proximal fluid discoveries are 
diluted in the bloodstream, and their concentrations are in the range of low nanograms per 
milliliter. This amount, contained in the human plasma sample, has to be analyzed within all 
other proteins of which concentrations span up to 12 orders of magnitude.28,29 
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1.3.2 Utilizing mass spectrometry for multiplexed quantitation 
 
Protein quantitation methods involving label-free and chemical derivatization approaches 
in mass spectrometry have become increasingly important in the analysis of complex biological 
samples.30,31 To increase the sample throughput potential of the analysis, chemical 
derivatization-based methods introduce chemical tags, facilitating simultaneous quantitation in a 
single analysis. Protein quantitation methods that utilize chemical derivatization are generally 
classified into isobaric and mass-difference tagging approaches.  
 
Mass spectrometry-based quantitation methods for proteins involving isobaric and mass-
difference tagging reagents have been continually explored on the basis of ease of preparation 
and reduced analysis cost. Identification and relative quantitation of proteins using these reagents 
are carried out in single-stage mass spectrometry analyses or tandem MS (MS2 or MS3) 
experiments. Table 1.1 lists the reagents and the multiplexing capability comparison of each 
technique. Commercially available 4-plex and 8-plex isobaric tags for relative and absolute 
quantitation (iTRAQ)32, 6plex and 10-plex tandem mass tags (TMT)33-35, as well as variant mass 
tags dimethylated leucines (DiLeu)31, deuterium isobaric amine reactive tags (DiART)36,37, solid 
phase isobaric mass tagging (SPIMT)38, mass-balanced isotope dipeptide tags (MBIT)39, 
cleavable isobaric labeled affinity tag (CILAT)40, isobaric peptide termini labeling (IPTL)41, and 
pseudo-isobaric dimethyl labeling (pIDL)42 are among some of reported isobaric reagents used. 
On the other hand, examples of mass-difference tagging reagents include isotope-coded protein 
label (ICPL)43, isotope-coded affinity tag (ICAT)44, neutron-encoded chemical labels 
(NeuCode)45, and reductive methylation46-48 approaches. However, although labeling is highly 
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efficient, both isobaric and mass-difference tagging reagents require isotope labels to increase 
their sample throughput potential. Furthermore, the high cost of commercial isobaric reagents 
limits their application as routine MS-based quantitative proteomics tool.30,49 
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Table 1.1. Multiplexing in mass spectrometry for quantitative analysis. 
Reagent 
 
Required Resolving 
Power of Instrument 
Quantitation 
Mode 
MS used Multiplexing References 
iTRAQ - MS2 MALDI-
MS/MS 
8-plex Pottiez, et al32 
2012 
TMT MS2 minimum 
35,000 and 30,000 at 
200m/z 
MS2 Q Exactive 
Orbitrap and 
Orbitrap 
Elite 
10-plex Werner, et al35 
2014 
 MS1 120,000; MS2 
quant 60,000 
MS2 Orbitrap 
Fusion 
10-plex Erickson, et al50 
2015 
 MS2 30,000, MS3 
performed 
MS3 LTQ 
Orbitrap 
6-plex Ting, et al51 2011 
Hyperplexed mass tags 
(SILAC + TMT) 
MS1 30,000; MS2 
7,500 
MS2 LTQ 
Orbitrap 
Velos 
54-plex (18-
plex of 3 
targets) 
Everly, et al52,53 
2013  
 
DiLeu (Dimethylated Leucines) MS1 120,000; MS2 
60,000 
MS2 Orbitrap 
Elite 
12-plex Frost, et al54 2015 
 
- MS2 IM-MS/MS 4-plex Sturm, et al55 2014 
DiART (deuterium isobaric amine reactive 
tags) 
- MS2 LTQ 
Orbitrap 
4-plex Ramsubramaniam, 
et al37 2013 
MBIT (mass-balanced isotope dipeptide 
tag) 
- MS2 MALDI 
MS/MS 
2-plex Suh, et al56 2011 
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CILAT (cleavable isobaric labeled affinity 
tag) 
- MS2 MALDI-
MS/MS 
12-plex Zeng, et al40 2009 
IPTL (isobaric peptide termini labeling) MS1 70,000 and 
MS2 35,000 
MS2 Q Exactive 
Orbitrap 
3-plex Koehler, et al41 
2013 
pIDL (pseudo-isobaric dimethyl labeling) MS1 60,000 and 
MS2 30,000 (mass 
defect-based) 
MS2 LTQ 
Orbitrap 
Velos 
4-plex Zhou, et al42 2013 
PAL (protected amine labels) MS1 240,000 and 
MS2 30,000 
MS2 LTQ 
Orbitrap 
6-plex Ficarro, et al57 
2014 
cPILOT (combined precursor isotopic 
labeling and isobaric tagging) and 
cysDML (cysteine-selective dimethyl 
labeling) 
MS1 60,000 MS2 LTQ Orbitap 
Velos 
12- to 16-plex Evans and 
Robinson 2013, 
Gu, et al58,59 2015  
 
CIT (Caltech isobaric tags) - MS2 LTQ 
Orbitrap 
2-plex Sohn, et al60 2012 
NeuCode MS1 survey 30,000; 
MS2 quant 
scan  480,000 (mass 
defect-based) 
MS2 Orbitrap 
Elite 
12-plex Hebert, et al45 
2013 
Dimethyl labelling - MS2 - 5-plex Wu, et al46 2014 
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1.3.3. The sample throughput limitation of current mass spectrometry methods 
  
Contrary to antibody-based methods such as Western-blot, ELISA or 
immunohistochemistry, MS-based methods do not require immunograde antibodies developed 
for individual or panel of proteins. However, the capability of the application of current 
quantitative reagent toolbox after the discovery phase can be arguably conceded since their 
utility is not ideal for targeted quantitation in multiple samples.61 The mode of selected reaction 
monitoring (SRM) MS, or multiple reaction monitoring (MRM) MS provide multiplexing 
capability to analyze multiple analytes in one sample. In terms of sample (throughput) 
multiplexing, existing MRM methods have low sample throughput. The sample throughput has 
been limited to three, where the isotopic reagents used for labeling are iTRAQ counterparts, 
called mTRAQ. The structures of mTRAQ are shown in Figure 1.3, where the peptide reactive 
group is shown in green, and the isotopic variants in pink. 25 
 
 
Figure 1.3. Structure of mTRAQ reagents for triplex analyte and sample multiplexing in MRM. 
 
Δ0 
Δ4 
Δ8 
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1.4. Multiple reaction monitoring mass spectrometry  
 
1.4.1. Overview and the multiplexing potential of MRM methods 
 
Clinical and industrial applications of MRM MS exploit the enhanced accuracy and 
specificity of the method for analyte quantitation. MRM modes of analysis are performed on 
triple quadrupole (QqQ), where Q1serves as the first mass analyzer, q2 as collision cell, and Q3 
as the second mass analyzer. Quantitation is achieved in tandem fashion by monitoring 
transitions of precursor ion (peptide) to fragment (b- or y-) ions.62 Fragmentations wherein the 
charge is retained in the N-terminus are called b-ions, while y-ions carry the C-terminus. Figure 
1.4 depicts the schematic for transition monitoring: analytes of interest are selected in Q1, 
fragmented, and finally, specified fragments are analyzed in Q3. 
 
 
Figure 1.4. The precursor-to-fragment transition diagram in MRM analysis. 
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As mentioned, current MS methods such as MRM are capable of multiplexed analysis of 
multiple proteins in a single sample. More recently, MRM-based multiplexed quantitation of 
more than a hundred proteins in plasma samples has been reported. The application of such 
methods in the later validation phase, however, is inhibited by their low sample throughput. 7 
 
1.4.2. Ultrathroughput multiple reaction mass spectrometry 
  
A novel technology developed in our research laboratory, called Ultrathroughput 
Multiple Reaction Monitoring MS (uMRM MS), is an integration of non-isotopic peptide 
derivatization and liquid chromatography (LC) stable isotope dilution (SID) MRM MS.49 uMRM 
MS breaks through the bottleneck of the low sample throughput of all MS methods, transforming 
the standard MRM technique into a high-throughput potential that allows for one-experiment 
quantitation of a target protein (or several proteins) in many human serum or plasma samples. It 
can then be optimized and further utilized for the validation of candidate biomarkers in large 
numbers of patient samples for clinical applications. 
 
1.5. Dissertation objectives and goals 
  
1.5.1. Targeted quantitative analysis for cancer biomarker validation via N-in-1 
ultrathroughput MS 
 
This work presents a new cost-effective technology that integrates MRM and peptide 
derivatization (labeling or tagging) using a library of in-house synthesized non-isotopic reagents 
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to quantify low-abundant model protein biomarker in multiple samples. The derivatizing 
reagents, termed peptidyl reagents, are short peptides bearing varied N-termini modifications. 
Peptidyl reagents have high structural tunability and can be readily prepared through inexpensive 
solid-phase peptide synthesis. When sample-specific derivatization of signature peptides is 
achieved, a one-experiment MRM analysis of pooled samples will enable a high sample 
throughput quantitation of the target protein biomarker.  
 
Typically in validation studies involving thousands of patient-control samples, less than 
ten protein candidates are analyzed.7 The uMRM technology offers the following advantages as a 
bioanalytical platform: sample throughput advantage, flexibility, and immediate impact. Unlike 
current gold standard immunoassays for biomarker validation, uMRM is mass spectrometry-
based technique; thus it does not require the use of immunograde antibodies and is faster and 
more economical to develop. Figure 1.5 compares uMRM and ELISA workflows. In this study, 
the novel approach can be adapted in such ways that it is flexible across different biomarker 
candidates. The innovative nature of uMRM principle can also be translated to take advantage of 
the latest mass spectrometry instrumentation, as it is not limited to the use of conventional 
instruments for MRM measurements. It transforms the intrinsic MS capability of analyzing 
multiple analytes in a single experiment into the sample throughput dimension that will quantify 
common analytes in multiple samples.  
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1.5.2. Utilizing peptide derivatization technique for global targeted proteomic applications 
 
Peptide derivatization using peptidyl reagents offers signal enhancement for increased 
analytical detectability in mass spectrometry. Thus, the signal enhancement and sample 
multiplexing capability of the derivatization technique were then further investigated within 
proteomic profiling and derived towards a global quantitative approach. 
 
 
Figure 1.5. Highlighting the advantages of uMRM in comparison with ELISA. 
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Chapter 2. Peptide derivatization using peptidyl reagents for high signal yield screening 
 
2.1. Introduction 
 
Mass spectrometry (MS), combined with front-end separation techniques, is intrinsically 
capable of examining large numbers of analytes in a single experiment. These analytes can either 
be different molecules in a particular sample (analyte multiplexing) or common molecules that 
carry sample-specific mass tags (sample multiplexing). In the latter case, mass tagging is 
achieved via differentially labeling analytes with stable isotopes in a sample-specific manner; the 
isotope incorporation can be metabolic, enzymatic, or chemical.1 The relative mass spectra 
intensity of the differentially-tagged molecules allows for quantitation. In the protein biomarker 
regime, the analytes are peptides that result from proteolytic treatment of human proteome 
samples, e.g., sera, and these peptides are used as quantitation surrogates. Sample-specific 
tagging of common peptides in different samples can be achieved by chemical derivatization of 
peptides using isotopic reagents. There are collections of commercial and research-grade isotopic 
reagents in the toolbox of mass spectrometry-based quantitative proteomics. Quantitation of the 
isotope-labeled peptides are carried out by single-stage analysis using mass-difference tagging 
reagents, or using isobaric tagging chemicals for tandem MS (the so-called MS2 or MS3) 
experiments to monitor quantitation reporter ions produced from differentially-tagged peptides. 
 
Multiplexing samples for a single experiment, or increasing the sample throughput for 
MS analysis, is continuously being pursued. Utilization of the mass defect of peptide fragment 
ions for multiplexed proteomic quantitation becomes feasible using isotopologues of commercial 
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reagents and can be credited to contemporary high-resolution mass spectrometers. Small 
differences in the mass defect of quantitation reporter ions can now be readily resolved.2  A 
common challenge for the isobaric mass tagging strategy, however, originates from the co-
selection of precursor ions that have close retention time and mass-to-charge ratios. This co-
selection leads to compressed ratios of the reporter ions,3 because all peptides in a particular 
sample are derivatized with the same reagent. Methods of MS3-based quantitation and gas-phase 
purification4 have been proposed to address this issue, but at the expense of relatively reduced 
sensitivity.5 Further increases in the sample throughput of MS analysis can exploit a modular 
principle for workflow design, through the combined use of the isotopic quantitation reference 
and peptide derivatization. Hyperplexed proteomic quantitation of 18 samples, using isotopic 
reagents, has been presented.6,7 Also reported was a proof-of-concept demonstration of one-
experiment quantitation of 25 samples using non-isotopic reagents for peptide derivatization.8 
Sequential labeling of peptides with dual sets of isotopic reagents provides yet another route to 
increase the sample throughput for MS analysis, allowing for multiplexing of 12-16 samples.9,10  
 
However, it is expensive to use isotopic reagents for multiplexing analysis of large 
numbers of samples. The cost of analysis increases more than proportionally with the sample 
number increase. The structural diversity of isotopic reagents that can be economically 
synthesized is also limited. Furthermore, quantitation of low-abundance proteins in sera requires 
large sample volumes in order to enable MS analysis with desired quantitation limits; it becomes 
cost-prohibitive to use isotopic reagents to derivatize peptides in the digests of human sera in 
large volumes (e.g., 100 µL) and large numbers (100’s to 1000’s).  
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Setting aside the multiplexing requirement, simplistic chemical modification of peptides 
had long been performed in MS approaches. Chemical modification is performed to achieve 
three major goals: (1) to introduce quantification labels, (2) to enhance spectral signals of 
proteotypic peptides, and (3) to simplify the complexity of spectral data.11 Techniques for the 
modification of the peptide termini, both N- and C-terminal, enabled global analysis of 
proteomes. The N-termini have gained more popularity as modification target. Modification in 
the N-terminal had been categorized, through a set of labeling experiment utilizing Iodine-
containing compounds for derivatization reactions.12 Generally, they are grouped as passive and 
active fragment ion mass defect labeling (FIMDL). Their classification is based on the 
fragmentation behavior of the peptide, whether or not the modifying group affects the gas-phase 
fragmentation. FIMDL modifying groups can be observed in the spectrum depending on charge 
distribution and consequently the relative abundance of generated fragment ions. 
 
Herein, the techniques of simple chemical modification are adapted to prepare short 
peptides (modified), termed peptidyl reagents, and subsequently use them as derivatizing tools 
for quantitation.  Short peptides will be prepared through standard Fmoc-chemistry solid phase 
peptide synthesis using trityl polystyrene resins preloaded with the first amino acid. After the last 
deprotection step, with the peptides still bound to the resin, the free N-terminal will be modified 
with various capping reagents. The products will then be used to derivatize standard signature 
peptides of model biomarkers, prostate specific antigen (PSA) and cystic fibrosis transmembrane 
conductance regulator (CFTR).  
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Prostate specific antigen, other names include Kallikrein-3, Gamma seminoprotein, P-30 
antigen, and semenogelase (www.uniprot.org), is a widely used protein biomarker for prostate 
diseases such as prostate cancer and benign prostatic hyperplasia. Its function is to hydrolyze 
semenogelin-1, thus liquefying the seminal coagulum.13,14 On the other hand, the deficiency of 
protein CFTR in plasma membrane expression and function results in diminished chloride ion 
transport, consequently developing into pathological progression of cystic fibrosis.15 
Derivatization methods will be developed for PSA and CFTR01 signature peptides, and will then 
be further validated for increased sample throughput application. 
 
2.2. Preparation of peptidyl reagent library 
  
2.2.1. Experimental 
   
2.2.1.1. Research Facilities 
 
All sample preparations were performed in a Biosafety Level 2 laboratory within the 
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). MS 
characterizations are performed using AccuTOF DART MS (JEOL), located in the MS facility of 
the Department of Chemistry (R403). 
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2.2.1.2. Materials and reagents 
 
Pre-loaded 2-Cl-trityl polystyrene resins, Fmoc L-amino acids were obtained from Matrix 
Innovation (Quebec, Canada).  Solvents dimethylformamide (DMF), dimethylacetamide 
(DMAc), dichloromethane (DCM), tetrahydrofuran (THF), methanol (MeOH), LC-MS grade 
acetonitrile (ACN), and diethylether were purchased from Sigma-Aldrich (St. Louis, 
MO).   Fmoc-β-Ala-OH, Fmoc-4-Abu-OH, and Fmoc-5-Ava were purchased from Advanced 
ChemTech (Louisville, KY). O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-
phosphate (HBTU) was obtained from Chem Impex (Wood Dale, IL). N,N-
Diisopropylethylamine (DIEA), N-Methylmorpholine (NMM), piperidine, acetic anhydride, 
propionic anhydride, valeric anhydride, formaldehyde, pyridine-borane complex, 2-picoline-
borane complex, acetic acid, O-phthaldialdehyde (OPA), dimethylaminobenzoic acid (DMABA), 
diethylaminobenzoic acid (DEABA), picolinic acid, triisopropylsilane (TIPS), potassium cyanide 
(KCN), ninhydrin, and ethanol (EtOH) were also from Sigma-Aldrich (St. Louis, MO). Pyridine 
and phenol were from J.T. Baker (Center Valley, PA). Glutaraldehyde (Gl), trifluoroacetic acid 
(TFA), and formic acid (FA) were purchased from Fisher (Pittsburgh, PA).  
 
Peptide synthesis was performed in 2-frit, 20 µm extraction reservoirs (UCT, Bristol, 
PA). Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized water. 
Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven (Fisher 
Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation of samples 
was performed on Hula Mixer (Invitrogen, Grand Island, NY) or Thermomixer R (Eppendorf, 
Hauppauge, NY). 
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2.2.1.3. Fmoc-based solid-phase peptide synthesis of short peptides 
 
Solid-phase peptide synthesis (SPPS) was performed on 2-Cl trityl polystyrene resin 
preloaded with amino acid. In a clean tube, a solution containing Fmoc-amino acid (3-fold 
excess), HBTU (3-fold excess), and DIEA (5-fold excess) in DMF were prepared. The solution 
was added to the polystyrene resin contained in a fritted reservoir, previously swelled with DMF 
and drained. The coupling step was performed by incubating the reaction mixture for 90 mins at 
room temperature, and washed with DMF, DCM, MeOH, and DMF. Fmoc-deprotection was 
carried out by incubating the resin with 25% piperidine in DMF for 90 mins. Coupling and 
deprotection steps correspond to one cycle of synthesis. The resin was then washed with DMF, 
DCM, MeOH, DMF, and diethyl ether. After a series of coupling cycles, the polystyrene resin 
with bound short peptides, were dried in vacuum and stored at 4°C. 
 
The completion of each reaction step in SPPS can be visualized through Kaiser Test. 
Solution A was prepared from ninhydrin:EtOH [5:95 (w/v)], Solution B from phenol:EtOH [4:1 
(w/v)], and  Solution C from 1 mM KCN in H2O:pyridine [2:98 (v/v)]. Kaiser test was 
performed by transferring 1-2 mg of resin in a clear microcentrifuge tube. Two drops of Solution 
A, one drop of Solution B, and one drop of Solution C were added to the resin, respectively. The 
tube was then heated for 2-5 mins. Blue resins correspond to free amines, while clear/yellowish 
resins indicate protected N-terminal. 
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2.2.1.4. On-resin N-terminal modifications 
 
After a series of coupling cycles to prepare short peptides on-resin, various solid-phase 
N-terminal capping modifications (described below) were developed to generate the library of 
peptidyl reagents. In a separate tube, cleavage solution was prepared by mixing TFA:TIPS:H2O 
[900:50:50 (v/v/v)]. The cleavage solution was added to the reservoir containing dried resin and 
cooled in an ice bath for 10 mins. The reaction mixture was then incubated for 90 mins, followed 
by draining of peptide solution in a clean microcentrifuge tube. TFA was concentrated in 
vacuum oven, followed by precipitation of peptides in cold ether.  The peptides were dried in 
SpeedVac and lyophilizer before storing them in -20°C. 
 
Acylation with anhydrides. In a microcentrifuge tube, a solution containing 50 µL 
acetic, propionic, or valeric anhydride, 60 µL DIEA, and 890 µL DMF was prepared and added 
to 100 mg of dried resin with short peptides. The reaction mixture was incubated overnight. 
After incubation, the solution was drained from the reservoir. The resin was then washed, dried 
and peptidyl reagents were cleaved as described in the above procedure. 
 
Acylation with picolinic acid. In a microcentrifuge tube, a solution containing 29 mg 
picolinic acid, 88 mg HBTU, 50 µL DIEA and 1 mL DMF was prepared and added to 100 mg of 
dried resin with short peptides. The reaction mixture was incubated overnight. After incubation, 
the solution was drained from the reservoir. The resin was then washed, dried and peptidyl 
reagents were cleaved as described in the above procedure. 
 
29 
 
Acylation with diethylaminobenzoic acid. In a microcentrifuge tube, a solution 
containing 173 mg DMABA, 350 mg HBTU, 200 µL DIEA and 1 mL DMF was prepared and 
added to 100 mg of dried resin with short peptides. The reaction mixture was incubated 
overnight. After incubation, the solution was drained from the reservoir. The resin was then 
washed, dried and peptidyl reagents were cleaved as described in the above procedure. 
 
Dimethylation.  To 100 mg of dried resin with short peptides, 286 µL formaldehyde, 
1080 µL MeOH, 246 µL pyridine-borane complex, and 132 µL acetic acid were added 
successively. The reaction mixture was cooled in ice for 10 mins. Overnight incubation with 
gentle swirling was performed. The reservoir cap was punctured to release gas buildup. After 
incubation, the solution was drained from the reaction mixture. The resin was then washed with 
MeOH, dried, and peptidyl reagents were cleaved as described in the above procedure. 
 
Dialkylation with glutaraldehyde. In a clean tube, a solution containing 704 µL 
glutaraldehyde, 352 µL THF, 704 µL MeOH, 246 µL pyridine-borane complex, and 132 µL 
acetic acid was prepared and added to 100 mg of dried resin with short peptides. The reaction 
mixture was incubated overnight. After incubation, the solution was drained from the reservoir. 
The resin was then washed with MeOH, dried, and peptidyl reagents were cleaved as described 
in the above procedure. 
 
Dialkylation with OPA. In a microcentrifuge tube, a solution containing 89 mg OPA 
and 142 mg 2-picoline-borane complex in 667 µL MeOH was prepared and added to 100 mg of 
dried resin with short peptides. The reaction mixture was incubated overnight. After incubation, 
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the solution was drained from the reservoir. The resin was then washed with MeOH, dried, and 
peptidyl reagents were cleaved as described in the above procedure. 
 
2.2.1.5. Split-and-pool preparation of peptidyl reagent sets 
 
To facilitate synthesis of several peptidyl reagent sequences in one mixture for screening 
purposes, each set of peptidyl reagents was prepared by performing split and pool method; 
starting on equal molar amounts of resins pre-loaded with different amino acids. Typically, a 
total of 1 g resin was split into 2 to 5 fractions. The resins were split evenly and transferred into 
reservoirs, followed by successive coupling cycles with different amino acids. After drying, the 
resins were recombined and split for the next coupling cycles, diagrammed in Figure 2.1. 
Subsequent common N-terminal capping modification, acid cleavage, and precipitation were 
then performed. The reagents were dried in SpeedVac and lyophilizer, followed by 
characterization in AccuTOF DART MS. From sets of reagents prepared for screening, a 
representative list is shown in Table 2.1. 
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Figure 2.1. Split-and-pool preparation of peptidyl reagent sets. A, B, C,…m are amino 
acids constituting multiple sequences in one pool. 
 
 
Table 2.1. Representative peptidyl reagents screened for uMRM analysis. 
Dimethyl Propionyl Acetyl Picolinoyl Pyrrolidin-1-yl Isoindolin-2-yl 
4-(Diethylamino) 
benzoyl 
Dim-βAL Pr-AFA Ac-FVG Pic-GGA Gl-VAL OPA-VFF DEABA-GGG 
Dim-βAG Pr-AGA Ac-FFG Pic-GFG Gl-VAV OPA-VLG DEABA-GLG 
Dim-βAA Pr-ALA Ac-FLG Pic-GGG Gl-VVG OPA-VGA 
 Dim-βAVA Pr-AFG Ac-FLL Pic-GLG Gl-VVA OPA-VFA 
 Dim-βAVG Pr-AGG Ac-VVV Pic-GGF Gl-AFVL 
  Dim-βAAVG Pr-VGVA Ac-VLV Pic-GAVV Gl-AFVF 
  … … … … … 
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2.2.2. Results and discussion 
 
To develop a repository of reagents that can efficiently derivatize proteome digests, 
design and synthesis of short peptides with various N-terminal capping groups were performed 
using a screening-based strategy.16,17  Following a series of coupling cycles to synthesize the 
short peptides, various solid-phase N-terminal modifications or capping (denoted as CapGr) were 
performed to generate the library of peptidyl reagents. These short peptides having modified N-
terminal, with a general form of CapGr-AAn…AA1 (n = 2, 3 or 4), comprise the peptidyl reagent 
library and are termed peptidyl reagents. Figure 2.2 shows the structures of N-terminal reagent 
modifying groups. Protocols for in-solution derivatizations obtained from literature needed to be 
modified and developed though solid-phase methodologies.12,18-22  
 
For a simplistic approach, only Fmoc-amino acids with no reactive side chains (alanine, 
glycine, leucine, phenylalanine, and valine) were used in this study. The peptide length was also 
limited to a maximum of four amino acid residues, and the N-terminus was capped to convert the 
primary N-terminal amine into groups that are inert during derivatization of proteome digests. 
Specifically, the N-termini of peptidyl reagents were capped with seven different functional 
groups through either acylation [acetyl, propionyl, picolinoyl, and 4-(diethylamino)benzoyl] or  
reductive dialkylation [dimethyl, pyrrolidin-1-yl (the product of glutaraldehyde), and isoindolin-
2-yl (the product of phthalaldehyde)]. For screening purposes, the reagents were prepared using 
split-and-pool strategy to generate a large number of reagents. The split-and-pool synthesis 
technique23 was used to prepare small libraries of peptidyl reagents on the small scale, starting 
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with 1 g of a mixture of trityl-Cl polystyrene resin preloaded with the first amino acid (equal 
moles); where each library contained 6-12 reagents. 
 
 
Figure 2.2. Selected N-termini modifications on the peptidyl reagents. These modifications 
served as N-terminal capping groups to increase the diversity of reagent repository. 
 
2.2.2.1. Optimization for improving the yield of the peptidyl reagent synthesis 
 
For comparison of dimethylation yield, the ideal composition and reagent ratio of 
modification solution were developed (Table 2.2). The resulting peptidyl reagent was cleaved 
from the resin and analyzed in MS. Ratio of dimethylated to unmodified peptide was found to be 
highest with 57:108:49:26.4 (CH2O/MeOH/PyB/HOAc) solution and overnight incubation at 
room temperature.  
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Table 2.2. Optimization results for on-resin dimethylation. Reaction yield is shown as a ratio of 
modified to unmodified peptidyl reagent, as analyzed by MS. 
Modification solution 
Unimethylated:
unmodified 
Dimethylated: 
unmodified 
114:216:49:48 (CH2O/MeOH/PyB/NMM), O/N, RT 14:1 59:1 
57:108:49:48 (CH2O/MeOH/PyB/NMM), O/N, RT 36:1 146:1 
57:108:49:48 (CH2O/MeOH/PyB/NMM), 2h, RT 15:1 78:1 
57:108:49:26.4 (CH2O/MeOH/PyB/HOAc), O/N, RT 40:1 666:1 
57:108:98:48 (CH2O/MeOH/PyB/NMM), O/N, RT 52:1 134:1 
 
 
The same optimization was performed for glutaraldehydation, shown in Table 2.3. The 
highest intensity ratio of glutaraldehydated to unmodified peptide was obtained from 
141:70:141:49:26 (Gl/THF/MeOH/PyB/HOAc) solution and overnight incubation at room 
temperature. Attempts were made to generate more modification schemes for increased number 
of reagents. With succinic dialdehyde modification, the compound was synthesized in-house. 
Optimized procedure with 10:40:50 (HOAc/MeOH/2,5-dimethoxytetrahydrofuran) solution 
incubated at 37°C for overnight resulted to higher yield in the MS. However, when used for on-
resin modification of peptide, the yield was only 0.6:1 (modified/unmodified).  
 
Alkylation reactions with butyraldehyde and hexanaldehyde, as well as modification with 
dimethylaminobenzoic acid were also developed, but the on-resin preparation methods were 
inefficient. To recount the methods, the following were performed for the unsuccessful 
modifications and would thus require optimization if adapted. The corresponding solutions were 
prepared and added to 100 mg of dried resin with short peptides, followed by overnight 
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incubation, washed, and cleaved as per protocol. For alkylation with butyraldehyde, a solution 
containing 752 µL butanal, 540 µL MeOH, 123 µL pyridine-borane complex, and 76 µL acetic 
acid was prepared. With hexanaldehyde, the solution contained 541 µL hexanaldehyde, 540 µL 
MeOH, 123 µL pyridine-borane complex, and 76 µL acetic acid. Lastly, for the modification 
using dimethylaminobenzoic acid, the incubating solution consisted of 148 mg DMABA, 350 mg 
HBTU, 200 µL DIEA and 1 mL DMF. 
 
Table 2.3. Optimization results for on-resin glutaraldehydation. 
Modification solution Glutaraldehydated:unmodified 
141:70:141:49:48 (Gl/THF/MeOH/PyB/NMM), O/N, RT 16:1 
141:70:141:49:48 (Gl/THF/MeOH/PyB/NMM), )/N, 37°C 36:1 
141:70:141:49:26 (Gl/THF/MeOH/PyB/HOAc), O/N, RT 2973:1 
141:141:70:49:48 (Gl/THF/MeOH/PyB/NMM), O/N, RT 203:1 
 
2.3. Preparation of peptidyl reagent activated esters and derivatization of standard peptide 
mixtures 
  
2.3.1. Experimental 
   
2.3.1.1. Research Facilities 
 
All sample preparations are performed in a Biosafety Level 2 laboratory within the 
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). LC-TOF-
MS will be performed using 10ADvp system (Shimadzu, Kyoto) and quadrupole time-of-flight 
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(QTOF) mass spectrometer (QSTAR Elite, Applied Biosystems), located in the MS facility of 
the Department of Chemistry (R403). 
 
2.3.1.2. Materials and reagents 
 
Dimethylacetamide (DMAc), LC-MS grade acetonitrile (ACN), 4-(4,6-Dimethoxy-1,3,5-
triazin-2-yl)-4-methylmorpholinium chloride (DMTMM), N-Methylmorpholine (NMM), and 
1,4-Dimethylpiperazine (DMPipZ) were purchased from Sigma-Aldrich (St. Louis, MO). 
Trifluoroacetic acid (TFA) and formic acid (FA) purchased from Fisher (Pittsburgh, PA). 
Standard synthetic peptides were from Peptide 2.0 (Chantilly, VA), AnaSpec (Fremont, CA), and 
Thermo Fisher (Pittsburgh, PA). Direct-Q3 water system (Millipore, Billerica, MA) was used to 
purify deionized water. Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum 
oven (Fisher Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation 
of samples was performed on Hula Mixer (Invitrogen, Grand Island, NY) or Thermomixer R 
(Eppendorf, Hauppauge, NY). 
 
2.3.1.3. Derivatization of standard peptides using peptidyl reagent sets 
 
Activated peptidyl reagent was prepared by adding 1 µmol/11 µL DMTMM in DMAc, 9 
µL of NMM:DMAc [1:80 (v/v)] and 20 µL DMAc in a tube containing dried aliquot of 2.5 µmol 
peptidyl reagent. The resulting solution was incubated for 1 hr at room temperature. 
Immediately, 30 µL of the activated reagent was transferred into another tube with 5 µL of 
DMPipZ:DMAc [1:10 (v/v)]. A 12 µL aliquot from the resulting solution was added to the 
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lyophilized standard peptide aliquot. The standard peptide mixture contained 1 nmol each of 
CFTR signature peptide CFTR01 and PSA signature peptides SVI, HSQ, and LSE. In addition to 
signature peptides, the standard mixture consisted of synthetic peptides YGGFLR, LSEAVTLK, 
IVGGWEK, NSILTETLR, HSTETLR, and SVIGGR. The sample was incubated overnight at 
room temperature. The reaction was then quenched with 12 µL of ice-cooled 20% FA for 30 min 
and diluted to 75 µL with H2O. A 5 µL aliquot was transferred into another tube containing 85 
µL H2O, 5 µL SVI*, and 5 µL HSQ* IS solutions. The samples were then analyzed using LC-
TOF-MS and LC-MRM-MS. 
 
LC-TOF-MS was performed using 10ADvp system (Shimadzu, Columbia, MD) and 
quadrupole time-of-flight (QTOF) mass spectrometers (QSTAR Elite, Applied Biosystems, 
Foster City, CA) and QTOFmicro, Waters, Milford, MA). The mobile phase binary gradient 
system had solvent A of FA:ACN:H2O [2:10:988 (v/v/v)] and solvent B of FA:H2O, ACN 
[2:10:988 (v/v/v)]. LC separation was performed with reversed-phase column (Hypersil GOLD, 
1.9 μm, 100 x 1.0 mm, Thermo Scientific, Waltham, MA) set at 60 °C, with flow rate of 80 
µL/min. The chromatographic gradient was run with 2% B at 0 min → 60% B at 20 min → 80% 
B at 23 min → 80% B at 26 min → 5% B at 27 min → 5% B at 30 min. Key MS instrument 
parameters were set at IS 5500 V, GS1 20, CUR 20, DP 30, DP2 15, FP 280, CAD 10, and m/z 
range 300-1500. LC-MRM-MS was performed using the 10ADvp system described above and 
4000 QTRAP triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA). 
Similar chromatographic parameters were employed. Key MRM MS instrument parameters were 
set at IS 4000 V, GS130, CUR 20, IHT 150, EP 10, and CXP 10. 
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2.3.2. Results and discussion 
 
2.3.2.1. In-situ activation and derivatization scheme 
 
The reagent libraries were screened to develop reagents that could enhance the MS 
detection of SVI and CFTR01. Since >95% chemical conversion is the target chemical 
conversion yield  for the peptide derivatization in this work, selection of peptidyl reagents and 
derivatization conditions were optimized. When conversion yield of 44% for short peptide 
YGGFLR derivatizations was obtained with DMTMM as the activating reagent, the labeling 
method was further optimized and applied to CFTR01 and PSA model peptides. In experiments 
with single peptidyl reagent (Ac-AFL-OH), the optimum condition for CFTR01 derivatization 
was with DMTMM and PyBOP as activating reagents, both with >98% conversion yield for Ac-
AFL-NSILTETLHR product. Peptide samples were then derivatized following in-situ activation 
via formation of activated triazine esters of peptidyl reagents with DMTMM (Scheme 1). Figure 
2.3 contrasts the structure of a peptidyl reagent, Ac-AFL, with mTRAQ reagents in Figure 1.3 
 
Peptide mixture samples of CFTR01 (1 nmol) and SVI (1 nmol), together with eight 
other synthetic peptides constituting a total of 20 nmol of peptidyl amine groups, were 
derivatized with 2.5 µmol (theoretical) of each of the reagent mixtures. Figure 2.4 shows TOF-
MS/MS of CFTR01 derivatized by peptidyl reagents Ac-AFL and Dim-βAAFL. 
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a 
 
b 
 
 
Scheme 1. DMTMM-mediated derivatization scheme  (a) DMTMM-mediated activation of 
peptidyl reagent, Ac-AFL-OH; (b) followed by derivatization of Peptide CFTR01. 
 
 
 
 
Figure 2.3. Structures of peptidyl reagent Ac-AFL (acetylated) and activated Ac-AFL. 
 
 
Ac-AFL 
Ac-AFL activated 
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Figure 2.4. (a) LC-TOF-MS/MS spectrum of Ac-AFL-NSILTETLHR (CFTR01 derivatized 
with acetylated AFL (Ac-AFL), m/z 778.93 for doubly charged precursor ions). The reaction is a 
typical passive derivatization giving multiple derivatized b-ions and corresponding y-ions. (b) 
LC-TOF-MS/MS spectrum of Dim-βAAFL-NSILTETLHR (CFTR01 derivatized with 
dimethylated βAAFL (Dim-βAAFL), m/z 778.93 for doubly charged precursor ions). 
 
Both TOF-MS and MRM MS modes are used for screening. TOF MS screening was 
mainly for the ease of batch analysis. Eventually, however, MRM will be the mode of analysis 
for actual biological samples. MRM transition [M+2H]  y5 for peptide SVI derivatized by Ac-
AFL is shown in Figure 2.5. 
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Figure 2.5. Representative MRM transition structure of a doubly-charged derivatized precursor 
fragmenting to y5. 
 
2.3.2.2. Calculating percentage of chemical conversion and signal yield for mass 
spectrometry 
 
The extent of derivatization efficiency was determined by two quantitative parameters: 
(1) percentage of chemical conversion (PCC); and (2) signal yield for mass spectrometry 
(SYMS). PCC and SYMS were calculated for each peptide derivatization using Equations 1 and 
2, where Int 1 = PA or PH of underivatized peptide; Int 2 = PA or PH of labeled peptide; Int 3 = 
PA or PH of derivatized peptide; and R = concentration ratio of peptide to spiked labeled 
peptide.  Quantitative criteria were then set at >90% PCC and >100% SYMS for a peptidyl 
reagent to pass derivatization screening.  
 
𝑃𝐶𝐶 =  
(𝐼𝑛𝑡 2 × 𝑅)−𝐼𝑛𝑡 1
𝐼𝑛𝑡 2 × 𝑅
 ×  100%      Eq. 1 
 
𝑆𝑌𝑀𝑆 =  
𝐼𝑛𝑡 3
𝐼𝑛𝑡 2 × 𝑅
 ×  100%    Eq. 2 
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These two criteria were set to ensure that not only a reagent could effectively derivatize 
peptides (measured by PCC), but also importantly, the added steps of sample derivatization and 
cleanup did not lead to a detectability loss (measured by SYMS). After identifying reagents that 
yield suitable derivatizations, the procedure was then be adapted to develop a robust method for 
the analysis of the model protein biomarker in the study. The reagents were then individually 
synthesized on a larger scale and purified in an LC-UV system. 
 
2.3.2.3 Selection of activating reagent and reaction conditions 
 
Initially, to achieve optimum conditions, a number of activation schemes were employed 
and the resulting derivatization efficiencies were compared. Several activating compounds such 
as ethylene dichloride/N-hydroxysuccinimide (EDC/NHS), diisopropyl carbodiimide/N-
hydroxysuccinimide (DIC/NHS), benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP), and DMTMM were used to activate peptidyl reagent Ac-AFL-
OH. Activated Ac-AFL-triazine ester was then added to signature peptide CFTR01 at pH >8.0 
with bases DMP and triethylammonium bicarbonate buffer pH 8.0 (TEAB). Results from the use 
of different activating reagents and bases are summarized in Table 2.4. 
 
Extraction of activated reagent ester with DCM/H2O, which could remove unreacted 
compounds, resulted to lower SYMS (less than 10%). In this method, DMTMM and NMM were 
added in excess, followed by immediate extraction of unreacted reagents. The activated peptidyl 
reagent ester, retained in DCM layer, was then dried down in SpeedVac and reconstituted in. 
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DMAc. Different solvents used for derivatization with resulting PCC and SYMS are shown in 
Table 2.5, wherein DMAc appears to be the best solvent. 
 
Table 2.4. Various activating reagents and bases and their effect on PCC and SYMS. 
Activating 
reagents 
Base used in derivatization reaction 
DMP TEAB 
PCC, % SYMS, % PCC, % SYMS, % 
NHS/EDC 12.6 N/D 5.1 5.2 
NHS/DIC <1 N/D <1 N/D 
PyBOP 97.7 54.9 72.2 N/D 
DMTMM 99.9 378.5 83.4 33.0 
 
 
Table 2.5. Derivatization reaction solvents and their effects on PCC and SYMS. 
Ac-AFL-
NSILTETLHR 
DMAc 
1/10 
dilution, 
DMAc 
1/10 dilution, 
20% n-PrOH/ 
DMAc 
20%                          
n-PrOH/ DMAc 
5%
DIEA 
DMF 
PCC, % 92 18 90 96 43 87 
SYMS, % 117 36 7 15 23 75 
 
Upon formation of peptidyl reagent triazine ester after 1 hour, it was found that overnight 
reaction incubation was sufficient for obtaining PCC of >90%. Figure 2.6 illustrates increase in 
PCC observed with increasing derivatization time. Other optimization measures, listed in Table 
2.6, such as addition of HOBT, increased temperature, and quenching with hydroxylamine did 
not yield to significant signal increase. 
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Table 2.6. Relative signal enhancement effects of varied reaction conditions. 
Optimization Relative SYMS 
36 h reaction 0.7 
60 h reaction 0.1 
Higher temperature (37°C) 0.8 
Extracted with DCM/ H2O 0.1 
NH2OH-Quenched 1.0 
 
 
 
Figure 2.6. Time-course reaction dynamics for DMTMM-mediated derivatization of CFTR01 
with Ac-AFL.  
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2.3.2.4. Signal enhancement for proteotypic signature peptides of model biomarkers 
 
Passing reagents had varying residue sequences and capping groups. They produced a 
wide range of SYMS values for the derivatized peptides, up to 100-fold for CFTR01 and 50-fold 
for SVI. Complete screening list is provided in the Appendix. To investigate if there is a 
structural determinant controlling the MS signal enhancement, SYMS values for derivatized SVI 
peptides were plotted against their aliphatic index (AI) values (the acetyl capping group on the 
derivatizing reagents was not included in the AI calculation) and grand average of hydropathicity 
(GRAVY). 
 
AI is the relative volume of the aliphatic side chains of a protein. The calculation 
accounts for the amount of aliphatic side chains, namely alanine, valine, isoleucine, and leucine. 
The capping groups were not accounted for; the calculated values include the SVI sequence and 
derivatizing peptidyl sequence. Obtained from the Expasy site 
(http://web.expasy.org/protparam/protparam-doc.html), the equation for obtaining the aliphatic 
index (AI) is given by Equation 3: 
 
𝐴𝐼 =  X(𝐴𝑙𝑎) + 2.9 ∗ X(𝑉𝑎𝑙) + 3.9 ∗ (X(𝐼𝑙𝑒) + X(𝐿𝑒𝑢))                      Eq. 3 
 
Where X is the mole percent of each aliphatic residue, a is the coefficient of the relative 
volume of valine equal to 2.9, and b is the coefficient of the relative volume of isoleucine/leucine 
equal to 3.9. On the other hand, GRAVY is equivalent to the sum of the hydropathy values of all 
the amino acids in a protein or peptide sequence divided by the number of the residues, given in 
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Equation 4.  The values are obtained from the amino acid hydropathicity scale values from Table 
2.7.24 
𝐺𝑅𝐴𝑉𝑌 =  
∑H𝑛
𝑛
                                                              Eq. 4 
 
Table 2.7. Amino acid hydropathicity values for calculating GRAVY (adapted from Kyte and 
Doolittle, 1982). 
Amino acid Scale value 
Ala 1.800 
Arg -4.500 
Asn -3.500 
Asp -3.500 
Cys 2.500 
Gln -3.500 
Glu -3.500 
Gly -0.400 
His -3.200 
Ile 4.500 
Leu 3.800 
Lys -3.900 
Met 1.900 
Phe 2.800 
Pro -1.600 
Ser -0.800 
Thr -0.700 
Trp -0.900 
Tyr -1.300 
Val 4.200 
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A general decrease in SYMS was observed with the AI and GRAVY increase for 
acetylation. However, a similar effect was not apparent with reagents capped with a dimethyl 
group. Figure 2.7 compares the SYMS with the varying peptide properties. Dimethylated 
reagents were generally among the compounds with higher SYMS values. Among successful 
reagents derivatizing SVI (180 reagent candidates) and CFTR01 (102 reagent candidates), a 
common preference on the residue sequence of reagents was not observable for the MS signal 
enhancement, as shown in Figure 2.8. Conversion to derivatized product and signal enhancement 
are also assessed for the other signature peptides. Poor reproducibility and low PCC for 
HSQPWQVLVASK was generally observed. Low detection signals for LSEPAELTDAVK and  
IVGGWECEK were also observed. Figure 2.9 compares the SYMS obtained from SVI and 
CFTR01 derivatizations with common reagents, signifying peptide-specificity of the reaction. 
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Figure 2.7. Plots of SYMS against GRAVY (Grand Average of Hydropathicity) and AI 
(Aliphatic Index). A decrease in SYMS was observed with increasing GRAVY and Aliphatic 
Index values for reagents with acetyl capping group (Ac), but no trend was apparent with 
reagents having dimethyl capping group (Dim). 
 
Figure 2.8. Different N-terminal capping groups of peptidyl reagents and their effect on SYMS. 
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Figure 2.9. SYMS of common peptidyl reagents screened for signature peptides CFTR01 and 
SVI. Mixtures of peptidyl reagents were prepared via combinatorial split-and-pool method and 
screened to evaluate derivatization effects with CFTR01 and SVI. 
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Chapter 3. Ultrathroughput mass spectrometry for the N-in-1 quantitation of prostate 
specific antigen in human serum samples 
 
3.1. Introduction 
 
The signal enhancement information obtained from screening the peptidyl reagent library 
provided important perspectives on the workflow design of targeted protein biomarker 
quantitation in multiple samples. The key technological feature is the use of structurally diverse, 
non-isotopic reagents to provide the needed sample-throughput potential for ultrathroughput 
mass spectrometry (uMS) quantitation of surrogate peptides. We reported a particular 
demonstration for quantifying prostate specific antigen (PSA) in multiple serum samples; this 
particular workflow is termed as ultrathroughput MRM MS (uMRM MS).1 The use of 
“ultrathroughput” was introduced to distinguish uMRM MS from existing strategies that increase 
the sample throughput via speeding the analysis of each sample. The new technology provides a 
potential economical path to surpass the current sample-throughput potential afforded by isotopic 
reagents, transforming the standard MRM technique into a high sample-throughput (N-in-1) 
technology for biomarker applications. In contrast to isotopic reagents that exploit the principle 
of integrated design, the N-in-1 uMS workflow, depicted in Figure 3.1, is signified by separated 
quantitation and sample-coding modules.  
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Figure 3.1. N-in-1 uMRM MS workflow illustrating the quantitation and sample coding modular 
separation. 
 
Firstly, we separate the quantitation and sample-coding principles to highlight the 
economic advantages of the method. In the technology of uMRM MS, the quantitation reference 
is the isotopically labeled counterpart of a surrogate peptide target; samples are spiked with a 
common quantitation reference that carries stable isotopes. It is important to note that the 
isotopic quantitation reference is added only at comparable concentrations (e.g., at the 
equivalence to picograms or low nanograms of proteins per milliliter; a minute cost concern) 
with those of the endogenous peptide surrogate. Thus, only low amounts of isotopic quantitation 
reference (and thus decreased use of expensive stable isotopes) are needed, making the approach 
highly cost-effective. If stable isotopes were added to the samples through peptide derivatization, 
the quantity of isotopes used would be many orders of magnitude higher, considering that high 
abundance proteins (and thus their resulting peptides) are many orders of magnitude higher in 
moles2 and these peptides also consume the expensive reagents. In this study, the unique peptide 
SVILLGR, denoted as SVI, is the quantitation surrogate for model biomarker PSA. An 
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isotopically labeled counterpart, denoted as SVI* (SVIL[L-13C6
15N]GR), was custom-made as 
the common quantitation reference (Scheme 1b). Relative to the frequently used PSA surrogate, 
peptide LSEPAELTDAVK,3,4 the MS signal of SVILLGR was found to be about 40%.  
 
The second advantage is the use of inexpensive, non-isotopic reagents for sample-specific 
mass coding to improve the sample throughput. This removes the cost barrier involved in using 
integrated, isotopic reagents for proteomic quantitation. Further cost savings can be realized 
when serum samples of large volumes (e.g., 100 μL) are analyzed. To compete with highly 
sensitive immunoassays,5,6 the use of relatively large amounts of samples for quantitation with 
yet-to-be-more-sensitive MS instruments currently is a practical solution. For instance, if serum 
volume was increased from 10 μL to 100 μL, then the limit of quantitation could be increased by 
a maximal factor of 10. However, it is not economically feasible to use stable isotopic reagents to 
derivatize peptides from large volumes of sera. Total protein content in 100 μL of serum is 
around 8 mg, and their peptides would use tens of milligrams of reagents. A commercial set of 
isotopic reagents with six labeling states and 4 mg for each reagent can cost over $2,500 (as of 
May 2015); each is only sufficient for derivatizing peptides from 10 μL of non-depleted serum.  
 
The third advantage is the open-source development of chemicals for derivatizing 
peptides to achieve enhanced MS detection. Without the need for considering stable isotopes in 
the reagent design, the door to utilizing the chemical diversity is left wide open. Virtually any 
non-isotopic, reactive chemical becomes a potential candidate for derivatizing peptides and the 
selection of a particular chemistry structure is at the user’s choice. Many criteria can be used for 
the reagent selection, such as ease of synthesis, scalability, or commercial availability. The most 
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significant criterion, however, is the capability of a reagent to improve the MS quantitation limit 
for a target peptide. 
 
While peptides cannot be amplified like nucleic acids via the polymerase chain reaction, 
that chemical derivatization of peptides can increase MS signals of the molecules has long been 
recognized.7-9 The practical utilization of this signal enhancement strategy, however, has been 
limited by costly synthesis of stable isotopic versions of signal-enhancing reagents. This is a 
disadvantageous consequence of the integrated reagent design. The use of reagent isotopologues 
for peptide derivatization is the current practice in MS-based quantitative proteomics. Non-
isotopic reagents have been excluded so far, because different reagents have different separation 
and MS ionization properties which thus prevent accurate quantitation. 
 
3.2. N-in-1 quantitation of model cancer biomarker prostate specific antigen in serum 
  
3.2.1. Experimental 
   
3.2.1.1. Research facilities 
 
All sample preparations were performed in a Biosafety Level 2 laboratory within the 
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). The HPLC-
UV system (Shimadzu) used for the peptidyl reagent purification is located in R409. LC-TOF-
MS will be performed using 10ADvp system (Shimadzu) and quadrupole time-of-flight (QTOF) 
mass spectrometer (QSTAR Elite, Applied Biosystems). LC-MRM-MS analysis was performed 
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using the 10ADvp system described above and 4000 QTRAP triple quadrupole mass 
spectrometer (Applied Biosystems). The mass spectrometers are in the MS facility of the 
Department of Chemistry (R403). 
 
3.2.1.2. Materials and reagents 
 
Methanol (MeOH), dimethylacetamide (DMAc), LC-MS grade acetonitrile (ACN), urea, 
iodoacetamide (IAA), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMTMM), N-Methylmorpholine (NMM), 1,4-Dimethylpiperazine (DMPipZ), CHAPS (3-((3-
Cholamidopropyl)dimethylammonio)-1-propanesulfonate hydrate), boric acid, sodium phosphate 
monobasic monohydrate, sodium phosphate dibasic dehydrate, acetic acid and dimethyl 
pimelimidate (DMP) were purchased from Sigma-Aldrich (St. Louis, MO). Trifluoroacetic acid 
(TFA), formic acid (FA), sodium hydroxide, and DL-Dithiothreitol (DTT) were purchased from 
Fisher (Pittsburgh, PA). 
  
Standard synthetic peptides were from Peptide 2.0 (Chantilly, VA), AnaSpec (Fremont, 
CA), and Thermo Fisher (Pittsburgh, PA). Female serum was from BioChemed (Winchester, 
VA). Human prostate specific antigen was purchased from Lee Biosolutions (St. Louis, MO). 
Sequence-grade trypsin was purchased from Roche (Indianapolis, IN). Standard synthetic 
peptides were from Peptide 2.0 (Chantilly, VA), AnaSpec (Fremont, CA), and Thermo Fisher 
(Pittsburgh, PA). Anti-SVI antibody CON-1 was developed and purchased from Epitomics 
(Burlingame, CA). Dynabeads Protein G and Phosphate Buffered Saline (PBS) 10X Solution pH 
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7.4 were from Life Technologies (Grand Island, NY). Dynal-MPC-S magnetic particle 
concentrator was obtained from Invitrogen (Oslo, Norway). 
 
Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized (DI) 
water. Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven (Fisher 
Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation of samples 
was performed on Hula Mixer (Invitrogen, Grand Island, NY) or Thermomixer R (Eppendorf, 
Hauppauge, NY).   
 
3.2.1.3. Tryptic digestion of prostate specific antigen and spiked serum 
 
To 100 μg of sample (protein in NH4OAc buffer or pure serum) , 8M urea in 100 mM 
NH4OAc pH 8.0 buffer (100 μL) was added and the tube was vortexed for 30 sec. Additional 100 
μL of NH4OAc pH 8.0 buffer was added to dilute the sample. Reduction was carried out by 
adding 4 μL of 500 mM DTE for 30 min at 30°C and let to cool down, followed by alkylation 
with 15 μL of 500 mM IAA for 30 min at RT in the dark. Further dilution with NH4OAc pH 8.0 
buffer to a total urea concentration of 2 M was performed prior to digestion. Trypsin was added 
to the sample, with an enzyme-substrate ratio of 1:25. The sample was incubated overnight at 
37°C. To quench the reaction, 10% TFA was added (total TFA concentration of 2%, v/v) and 
incubated for 10 min. The resulting digests were subsequently desalted using Oasis HLB 
(hydrophilic-lipophilic balance) material, lyophilized, and stored at -20°C. 
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3.2.1.4. Sample cleanup by desalting 
 
The sample was ensured to have a pH of less than 3 by adding 20% FA. About 100 µL of 
HLB bulk material beads in ACN suspension was packed in an empty toptip. The beads are 
conditioned with (5 × 200 μL) ACN, drained manually using a plunger. Air bubbles are taken out 
using a narrow pipette tip and the beads are kept wet throughout the desalting process. The beads 
were further equilibrated with (3 × 200 μL) 5% (v/v) ACN + 95% (v/v) (0.1%, v/v of TFA in DI 
water). The sample was loaded to the equilibrated HLB beads, collecting the flow-through. The 
flow-through was reloaded and drained. The sample-containing beads were washed with (3 × 
200 μL) 0.1% (v/v) TFA, collecting the wash with the flow-through. Using a clean new tube for 
collection, 200 µL of 70% (v/v) ACN was used for eluting the bound peptides. The eluent was 
dried in the SpeedVac to remove organic solvent and subsequently lyophilized. The beads could 
be washed with 70% (v/v) ACN and left suspended in ACN for future reuse. 
 
3.2.1.5. Sample-specific derivatization of digests 
 
Each sample was assigned unique peptidyl reagent for sample-specific derivatization. 
The activated reagent was prepared by adding 1 µmol/11 µL DMTMM in DMAc, 9 µL of 
NMM:DMAc [1:80 (v/v)] and 20 µL DMAc in a tube containing dried aliquot of 2.5 µmol 
peptidyl reagent. The resulting solution was incubated for 1 hr at RT. Immediately, 8 µL of 
DMPipZ:DMAc [1:10 (v/v)] was added into each activated reagent and mixed. The activated 
peptidyl reagent solution was then added to the lyophilized digest and incubated overnight at RT. 
The reaction was then quenched with 58 µL of ice-cooled 20% FA for 30 min and concentrated 
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using speed vac (about 30 min) to dry out organic solvents. Each sample was then diluted to 1.5 
mL with H2O and subsequently desalted (Section 3.2.1.4), this time using 1 mL loads in 1 cc 
HLB cartridge set in vacuum manifold. Eluted samples were combined and concentrated using 
SpeedVac and lyophilizer, until the total volume is about 300 µL. Single peptide enrichment was 
performed (as below) on the pooled sample using 0.75 mg beads. The sample was reconstituted 
using 0.1% TFA and incubated at RT for 30 min. Finally, the sample was centrifuged at 13.2 
rpm for 30 min at 4°C, and analyzed in NanoLC-MRM MS. 
 
3.2.1.6. Immunoenrichment of derivatized signature and internal standard peptide SVI 
 
3.2.1.6.1. Immobilization of antipeptide antibody against peptide SVI 
 
Buffers and solutions. The following buffers were prepared for the immunoenrichment 
protocol. CHAPS Buffer (0.03% CHAPS in 1X PBS) was prepared from a solution of 1X PBS 
solution pH 7.4 from (10X stock) and used to dilute 0.03% CHAPS (v/v). Buffer A (0.1 M 
borated buffer pH 9.5) was prepared by dissolving 6.18 g boric acid in 800 mL DI water, 
adjusting the pH to 9.5 using 5 M sodium hydroxide, and finally diluting the solution to 1 L with 
DI water. Buffer B (0.1 M sodium phosphate buffer, pH 7.4) was prepared by dissolving 2.62 g 
sodium phosphate monobasic monohydrate and 14.42 g sodium phosphate dibasic dihydrate, the 
pH was checked to be 7.4, followed by diluting the solution to 1 L with DI water. 
 
Washing. A vial of Dynabeads Protein G was vortexed and centrifuged in high speed. 
The beads were then re-suspended by vortexing the vial in lower speed for >30 s. Four aliquots 
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of 50 μL (equivalent to 1.5 mg) were prepared. The beads were centrifuged for 3 s and placed on 
the magnet for 1 min to allow time to settle before removing the supernatant. To each tube, 
immediately, 200 μL of CHAPS Buffer was added, vortexed, and then centrifuged. The 
supernatant was removed to discard. This washing step was performed twice. Another 200 μL 
was added to re-suspend the beads, which were all pipetted out and transferred to a new tube. 
This was followed by washing the tubes with 50 μL of CHAPS Buffer, adding the wash to the 
new tube. The tubes were placed on the magnet for 1 min and the supernatant was removed to 
discard. 
 
Binding of antibody. Four tubes containing 10 μg (24 μL) of CON-1 Antibody for SVI 
(kept at -20 ˚C) diluted to 200 μL with CHAPS Buffer were prepared. Gentle pipetting was 
performed to mix the solution thoroughly to avoid generating bubbles. The antibody solutions 
were then transferred respectively to the tubes containing the beads, followed by washing with 
50 μL of CHAPS Buffer, adding the wash. The tubes were flicked to re-suspend the beads, 
sealed, and incubated in a HulaMixer for 30 min. For incubation, the HulaMixer had the 
following parameters: orbital 45 rpm (1 s), reciprocal 35° (5 s), and vibro/pause 1° (2 s). The 
tubes were centrifuged and placed on the magnet. The supernatant was then removed and kept. 
To wash the beads, 200 μL of CHAPS buffer was added to each tube. The tubes were flicked to 
re-suspend the beads and incubated at RT for 3 min. For incubation, the HulaMixer had the 
following parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), and vibro/pause 1° (3 s). The 
tubes were centrifuged, placed on the magnet, and the supernatant was collected to keep. The 
washing step was performed for two more times, discarding the supernatant.  
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Crosslinking. To each tube, 200 μL of Buffer A was added. The tubes were flicked to re-
suspend the beads, centrifuged, and while on the magnet removed of supernatant to be kept. The 
washing step was repeated once, discarding the supernatant. A 100 μL solution of Buffer A was 
then added to each tube. Meanwhile, the crosslinking solution was prepared freshly (10 mM 
DMP in 100 mM Borate Buffer) by dissolving 5.2 mg of DMP with 1600 μL of Buffer A. For 
each tube containing the beads and 100 μL Buffer A, a 400 μL aliquot of the crosslinking 
solution was added. Each tube was flicked, sealed with parafilm, and covered with foil. The 
tubes were then incubated at RT for 30 min in dark. For incubation, the HulaMixer had the 
following parameters: orbital 45 rpm (1 s), reciprocal 35° (3 s), and vibro/pause 1° (3 s). The 
tubes were centrifuged, placed on the magnet, and the supernatant was removed and discarded.  
 
Quenching. Briefly, the reaction was stopped by adding 500 μL of 50 mM Quenching 
Buffer (Tris pH 7.5). Each tube was flicked, sealed, and incubated at RT for 15 min with the 
following HulaMixer parameters: orbital 45 rpm (1 s), reciprocal 35° (3 s), and vibro/pause 1° (3 
s). The tubes were centrifuged, placed on the magnet, and the supernatant was removed and kept. 
To wash the beads, a 500 μL solution of Buffer B was added. Each tube was flicked and 
incubated at RT for 3 min with the following HulaMixer parameters: orbital 45 rpm (2 s), 
reciprocal 30° (5 s), and vibro/pause 1° (3 s). The tubes were centrifuged, placed on the magnet, 
and the supernatant was collected to keep. The washing step was performed for two more times 
using CHAPS Buffer, discarding the supernatant.  
 
Acid wash was then carried out to remove antibodies that were not cross-linked to the 
beads. To each tube, 200 μL of Acid Wash Buffer was added. The tubes were then flicked and 
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incubated at RT for 2 min with the following HulaMixer parameters: orbital 45 rpm (2 s), 
reciprocal 45° (5 s), and vibro/pause 1° (3 s). The tubes were centrifuged, placed on the magnet, 
and the supernatant was removed and kept. To wash the beads, a 500 μL solution of Buffer B 
was added. Each tube was flicked and incubated at RT for 3 min with the following HulaMixer 
parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), and vibro/pause 1° (3 s). The tubes were 
centrifuged, placed on the magnet, and the supernatant was collected to keep. The pH of the 
supernatant was measured. The washing step was performed for two more times using CHAPS 
Buffer, discarding the supernatant. Lastly, 150 μL of CHAPS Buffer was added to each tube. The 
suspension was pipetted gently and all beads were transferred to one new tube and mixed 
thoroughly. Additional 50 μL was used to wash each previous tube, collecting all washings to the 
new one. After mixing my repeated pipetting, 16 aliquots of 50 μL were prepared. Each tube 
then contained 0.375 mg beads and stored in the fridge. 
 
3.2.1.6.2. Immuno-affinity pulldown procedure  
 
Washing. The digest sample was ensured to have a pH of 8 (using PBS buffer-2% 
MeOH (v/v)). Meanwhile, an aliquot of beads with immobilized antibodies (0.375 mg) were 
centrifuged and placed on the magnet. The supernatant was removed to discard. The peptide 
solution was transferred to the tube containing the beads with immobilized antibodies, using 
additional 50 μL of CHAPS Buffer to wash the tube that contained the sample. The tube was 
flicked and incubated at RT for 2 hrs with the following HulaMixer parameters: orbital 45 rpm (1 
s), reciprocal 35° (5 s), and vibro/pause 1° (2 s). The tube was centrifuged, placed on the magnet, 
and the supernatant was removed and kept. To wash the beads, a 200 μL solution of CHAPS 
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Buffer was added. Each tube was flicked and incubated at RT for 3 min with the following 
HulaMixer parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), and vibro/pause 1° (2 s). The 
tubes were centrifuged, placed on the magnet, and the supernatant was collected to keep. The 
washing step was performed for two more times, discarding the supernatant. 
 
Elution. Immediately, a 200 μL solution of Elution Ready Buffer (20 mM NH4HCO3) 
was added to the tube. Using a wide-mouth pipette tip, the beads are re-suspended and 
transferred to a new clean tube to prepare for elution. While on the magnet, the supernatant was 
taken out to clean the previous tube, aiding in transferring the rest of the suspension. The 
washing step was repeated once, the tube was centrifuged, and the supernatant was discarded. To 
elute, 30 μL of Elution Buffer was added to the tube. The tube was flicked and incubated at RT 
for 2 min with the following HulaMixer parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), 
and vibro/pause 1° (2 s). The tube was centrifuged, placed on the magnet, and the supernatant 
was collected into a new tube. The elution step was repeated with 30 μL of Elution Buffer. 
Immediately, 150 μL of DI water was added to the eluent. The solution was vortexed and 
subsequently centrifuged using Centrifuge 5415 R at 16.1×103 rcf, 4˚C for 30 min. Afterwards, 
the tube was placed in the magnet and the solution was transferred to a new clean tube and 
lyophilized for storage (-20˚C) and MS analysis.  
 
Meanwhile, the beads are washed three time using 200 μL of Buffer E, incubating for 3 
min at RT with the following HulaMixer parameters: orbital 45 rpm (2 s), reciprocal 35° (5 s), 
and vibro/pause 1° (2 s). All the wash solutions are discarded. After the final wash, 50 μL of 
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CHAPS Buffer was added to transfer the suspension to a new tube, for storage. The used 
immobilized antibody suspension was kept at 4˚C.  
 
3.2.2. Results and discussion 
   
3.2.2.1. The methodology of modular N-in-1 uMRM protein biomarker quantitation 
 
Prostate-specific antigen (PSA), a 29-kDa protein, is the primary biomarker for prostate 
cancer and has a reported limit of quantitation of 1 ng/mL in serum.10,11 Clinically, a healthy 
serum contains <4 ng/mL PSA. Herein, PSA peptide SVILLGR (SVI) is selected as the signature 
peptide for uMRM measurements of the protein. Non-depleted female serum samples (analyzed 
for zero PSA content) were spiked with PSA, enzymatically digested using trypsin, spiked with 
SVILL*GR (SVI*), and derivatized with in-house synthesized peptidyl reagents in a sample-
specific manner. Trypsin is a protease that cleaves on arginine and lysine residues. The protein 
content of the commercially-obtained female serum was analyzed in Qubit fluorometer using 
Quant-iT protein assay kit, and found to be about 80 mg/mL. Figure 3.2 shows the methodology 
of the modular design of N-in-1 uMRM quantitation. 
 
MRM predicted transitions and peak area quantitation were analyzed using Skyline 
software. The following analytical figures of merit were the criteria for the robustness and 
reproducibility of the method: (1) validation of accuracy and reproducibility (<20% error with 
<20% CV) of the qualified peptide derivatizations; and (2) determination of limit of quantitation 
and dynamic range.  
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Figure 3.2. Procedure for the quantitation of PSA in multiple serum samples. After sample-
specific derivatizations, the samples will be pooled, processed, and quantified (PSA) in a single 
analysis. 
 
3.2.2.2. Mitigating the sample overloading and dilution limitations through 
immunoenrichment 
 
As PSA is among low-abundant proteins in the serum proteome, coupled with the high 
complexity of the matrix, reproducibility and MS overloading issues are the major challenges in 
the protein quantitation method presented. Analysis of low-abundant proteins in serum typically 
employs depletion techniques to eliminate high abundant proteins. Prior depletion of abundant 
proteins can be performed to address the overloading issue as well. Initially, a preliminary 
depletion experiment was performed, using Albumin/IgG Spin depletion column to strip the 
serum with high-abundant proteins and albumins. As expected, higher recovery and sensitivity 
was attained in the mass spectrometry analysis. However, this additional upstream sample 
processing is not practical when dealing with large number of samples, particularly when the 
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method is adapted for validation applications. Considering the number samples in the validation 
phase, it is not cost-effective to perform large-scale depletion. Therefore, an alternative 
downstream sample treatment is necessary to achieve a collective enrichment of target peptides. 
 
To deal with high sample complexity and to increase the sensitivity of the method, 
immunoaffinity enrichment technique for target peptide was performed prior to MRM analysis. 
The peptide level enrichment method, adapted from Stable Isotope Standard Capture by 
Antipeptide Antibody (SISCAPA), thus alleviates the depletion requirement to detect low-
concentration proteins targets.2 This step mitigates the overloading and dilution limitations in 
uMRM strategy applied for one-experiment quantitation of derivatized peptides for protein 
biomarker validation. The immuno-enrichment strategy removed non-target peptides and 
enriches already derivatized SVI and SVI* from the complex pooled nondepleted serum digest, 
illustrated in Figure 3.3. Polyclonal antibody immobilization and crosslinking for the target 
peptide pulldown was optimized for anti-SVILLGR, using Protein G Dynabeads. The custom 
polyclonal antibody was developed against the C-terminus of peptide SVI (noting that the 
peptide derivatization occurs at the N-termini of the peptides). 
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Figure 3.3. Sample pooling and immunoenrichment on the peptide level. 
 
Advantages of SISCAPA over immunoassays such as ELISA include lower cost and 
higher quality assay in general. In contrast to SISCAPA methods, immunoassays use monoclonal 
antibodies with very high analyte specificity, using one antibody reagent for each sample.2,12-14 
Therefore, the use of a single antibody reagent in the uMRM workflow is less expensive and 
more importantly, simpler. Quantitation with SISCAPA-derived techniques also presented 
results of sufficient sensitivity, reproducibility and robustness, analyte structure characterization, 
detection of interference, ease of multiplexing, and improved throughput.15 Analytical 
parameters for SISCAPA-MRM include (1) selection of proteotypic peptides, (2) selectivity, (3) 
limit of quantitation, (4) linear response and recovery, and (5) reproducibility and 
transferability.6 
 
Initial efforts on SVI enrichment method development were exerted on standard peptide 
mixtures and pure PSA protein digests. Selected reagents from screening phase were individually 
synthesized and purified by high performance liquid chromatography. Digests of PSA samples 
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(2, 12, 122, and 184 ng/mL) were derivatized in a sample-specific manner using Pic-GGG, Pic-
GGA, Pr-VGA, and Pr-VLA. The resulting uMRM data for the surrogate SVI was found to be 
linear, shown in Figure 3.4. This preliminary 4-in-1 uMRM MS calibration result implicated the 
capability of the method to be adapted for the analysis of real clinical samples. 
 
Figure 3.4. Linearity analysis for 4-in-1 uMRM MS of derivatized PSA digests. 
 
3.2.2.3. Recovery and precision (9-in1) analysis 
 
In a validation recovery experiment for 16 reagent candidates, 16 aliquots of 100 µL of 
non-depleted sera were spiked with PSA at a concentration of 300 ng/mL and digested by 
trypsin. To each of the resulting digests, the same amount (5 pmol, experimentally determined in 
order to obtain similar MS signal intensities for both SVI and SVI*) of SVI* was added.  
Following the uMRM analysis workflow, 9 reagents resulted in strong MRM signals for the 
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derivatized SVI and SVI*. The chromatogram shows overlapping peaks corresponding to SVI 
and SVI* derivatized by nine peptidyl reagents listed, where dashed denote SVI while solid 
lines, SVI* (isotopic quantitation reference). This experiment was also designed to assess the 
quantitation precision for the uMRM workflow. In the derivatization of 9 successful reagents, the 
average ratio of CapGr-AAn…AA2AA1-SVI to CapGr-AAn…AA2AA1-SVI* was calculated to 
be 1.70 and the coefficient of variation to be 11.5% (Table 3.1). This precision was comparable 
to our previous proof-of-concept study (the coefficient of variation was 9.2%) on a simple 
protein digest.1  
 
 
Figure 3.5. Extracted ion chromatogram for quantitation of PSA in non-depleted sera in a 9-in-1 
uMRM MS analysis. 
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Table 3.1. Peak area ratio values calculated for the relative quantitation of non-depleted serum 
samples spiked at 300 ng/mL PSA through 9-in-1 uMRM MS. 
Peptidyl 
Reagent 
Peak Area 
Ratio 
CV 
Pr-VGA 1.58 11.1 
Pr-VLA 1.99 10.0 
Pr-AFG 1.38 21.7 
Pr-AGA 1.52 11.7 
Pr-ALA 2.02 12.3 
Pic-GLG 1.52 8.09 
Pic-GFG 1.88 16.0 
Pic-GGA 1.90 6.53 
Pic-GGG 1.53 5.56 
Average PA Ratio = 1.70 
Total CV = 11.5 
 
The high quantitation precision is another advantageous consequence of the modular 
design of the uMRM MS technology. The decoupled use of isotopic quantitation references and 
peptide mass coding allows for the passage of authentic quantitative information in original 
samples.1,16,17 The common quantitation reference SVI* was added before the derivatization 
and this practice mitigated quantitation problems associated with quantitative proteomics that are 
based on isotopic derivatization of peptides.18 In such a multiplexing experiment, each sample is 
separately derivatized with one reagent from a set of isotopologues, which brings in an added 
source for variations in accuracy and precision. It is unavoidable to have incomplete 
derivatization and side reactions, but the target SVI and the quantitation reference SVI* would 
experience the same degree of the derivatization imperfection. Additionally, the uMRM 
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technology can also be used in pair with isotopic proteins as quantitation references, which can 
further eliminate quantitation variations originated from protein-level sample preparations.19  
 
3.2.2.4. Low concentration (7-in-1) analysis 
 
Another investigation examined the practicality of using reagent candidates for the 
uMRM MS quantitation of PSA at concentrations that are clinically relevant.3,11 This 
investigation analyzed PSA in 1/10 non-depleted female serum. Seven out of the 14 reagent 
candidates successfully quantified equivalents of 600 pg of PSA on column using a 4000 
QTRAP (an earlier generation of triple quadrupole mass spectrometers), shown in Figure 3.6. 
The experiment was performed by Yuanyuan Shen in support of the study. Inset shows screening 
transitions for light and heavy Pr-ALA-SVILLGR in an early phase of reagent screening. 
  
A master stock of dried digest of PSA-spiked female serum, equivalent to the digest of 
200 µL of non-deplete serum containing 17 ng of PSA was first prepared and reconstituted with 
DMAC, Aliquots were made so that each contained an equivalent of 1 ng PSA with 1/10 (1/11.8 
exactly) serum as the background matrix. Fourteen aliquots were used for the experiment and 
peptides in each sample were derivatized with a unique reagent. All 14 samples were pooled and 
cleaned as described in the experimental section using immobilized antibody reagent. The 
cleaned, pooled sample was reconstituted with 10 µL of 0.1% TFA. Due to the limitations of the 
sample amount and instrument used, two sets of NanoLC uMRM analysis were run. First, each 
derivatized peptide was monitored for two transitions (in total, 56 transitions for all derivatized 
SVI and SVI*), to allow for identifying successful peptidyl reagents/derivatizations and best 
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transitions. This analysis only monitored 14 transitions in total, which made it possible to 
quantify the SVI peptide at an equivalence of 600 pg of PSA on column with a 4000 QTRAP. 
 
 
Figure 3.6. Extracted ion chromatogram for quantitation of clinically significant amounts of 
PSA in non-depleted diluted sera in a 7-in-1 uMRM analysis (credits to Yuanyuan Shen). 
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3.2.2.5. LOQ linearity (5-in-1) analysis 
 
To investigate linearity of the developed method at low, clinically significant concentration in 
serum, a 5-in-1 linearity analysis was performed. A single experiment on sample-specific 
derivatized SVI-spiked diluted serum digests established a calibration curve for SVI, using 5-in-
1 uMRM MS analysis. Digests samples containing 1, 2.5, 10, 30, and 60 ng/mL spiked with 8 
ng/mL SVI* were derivatized in a sample-specific manner using Dim-FVAA, Dim-GAG, Pr-
LGG, Pr- GFG, Dim-LGF to construct an N-in-1 calibration curve. The analysis resulted to R2 
value of 0.9923 (Figure 3.7). 
 
 
Figure 3.7. Calibration curve for 5-in-1 uMRM analysis of SVI. 
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3.2.2.6. Quantitation validation (15-in-1) analysis 
 
To validate the quantitation with higher number of samples on clinical concentration 
range, a 15-in-1 uMRM MS analysis was performed (Figure 3.8). SVI and SVI* (theoretically 
1:1) were spiked at equivalent concentrations of 1 to 60 ng/mL of SVI, which are clinically-
relevant. The samples were derivatized by the following reagents: Pr-ALA and Pr-ALG (1 
ng/mL), Pr-VLGG and Pr-LGG (2.5 ng/mL), Pr-GLGG and Pr-GLV (5 ng/mL), Pr-VLA and Pr-
GGA (7.5 ng/mL), Dim-GLVV and Pr-GFA (10 ng/mL), Dim-FVAA and Pr-GFG (20 ng/mL), 
Dim-LGF and Pic-GGG (40 ng/mL), Dim-GAG and Pic-GGA (60 ng/mL). Dim-GLVV 
derivatized SVI was not detected. The average ratio of SVI to SVI* was found to be 0.92 
(±0.09), while the overall CV was 10.3% for the replicate sample preparations. When plotted, an 
R2 of 0.9986 was obtained, wherein two samples for each concentration level were derivatized 
by two different peptidyl reagents and averaged. The CV was determined for three replicate 
injections of two different reagents and ultimately averaged for all samples. Only one sample 
spiked at 10 ng/mL was included in the plot as the other derivatized sample was not detected (the 
initial experiment was designed to be 16-in-1 uMS).  
 
Mass spectrometry analysis of serum digests is prone to complex matrix effects. Thus, 
the effect of derivatization reagents with different chemical structures on the chromatographic 
elution was carefully considered.  A particular pair of derivatized surrogate and reference 
peptides co-elute, thus experiencing the same matrix effect for ionization of both of the peptides. 
For some reagents wherein multiple peaks were observed in chromatograms, the total peak area 
was used for quantitation. The multiple peaks could be attributed to the presence of isomers in 
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reagents, which were in-house synthesized at low milligram scales. Nevertheless, this 
complication did not prevent accurate quantitation of SVI, because the signal for derivatized SVI 
was normalized by the concurrently derivatized reference, SVI*. It is interesting to note that due 
to their inherent hydrophobicity differences, derivatized SVI peptides have different retention 
times, spreading over the reversed-phase gradient. The elution order for the derivatized peptides 
was more or less predictable when retention time calculators were used (Table 3.2). In 
comparison, peptides derivatized with isotopic reagents (excluding certain deuterium labeled) of 
a given chemical structure co-elute. 
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Figure 3.8. Extracted ion chromatogram and linear plot for 15-in-1 uMRM analysis of SVI in 
non-depleted diluted sera. (a) Ion chromatograms of derivatized SVI and SVI* at clinically 
relevant concentrations. Serum digests were spiked with SVI (1 to 60 ng/mL) to mimic PSA in a 
proof-of-concept N-in-1 validation experiment. (b) Low-concentration plot for SVI constructed 
by a single, 15-in-1 uMRM MS. 
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Table 3.2. Comparison of predicted and actual chromatographic retention times of derivatized 
SVI in 15-in-1 uMRM MS. The capping group on the peptidyl reagent was not included in the 
prediction. Predicted RT is obtained from http://theorchromo.ru, while hydrophobicity index is 
from http://hs2.proteome.ca/ssrcalc-cgi/SSRCalcQ.pl. Where split peaks are specified, the major 
peak was considered for the order in actual relative elution (denoted by asterisk). 
Reagent 
Predicted 
RT 
Hydro-
phobicity 
Index 
Predicted 
Relative 
Elution 
Actual 
Relative 
Elution 
RT1 RT2 RT3 
Dim- 
Dim-GAG 42.15 12.51 1 1 63.71 - - 
Dim-FVAA 62.98 18.38 2 2 74.75 - - 
Dim-LGF 69.23 19.49 3 3 79.66 - - 
Pr- 
Pr-GGA 42.72 12.78 1 1 71.79* 73.1 - 
Pr-GLGG 50.75 15.39 3 2 77.98 - - 
Pr-LGG 49.07 14.57 2 3 80.72 - - 
Pr-GFG 54.09 16.31 5 4 82.96 - - 
Pr-ALG 53.71 15.73 4 5 83.62 - - 
Pr-VLGG 56.12 16.1 6 6 84.07 - - 
Pr-GFA 57.15 16.91 7 7 85.67* 88.64 - 
Pr-ALA 56.73 16.4 8 8 86.14* 91.44 - 
Pr-GLV 61.23 18.82 9 9 88.91* 95.55 - 
Pr-VLA 61.3 17.2 10 10 77.98 91.05* 96.99 
Pic- 
Pic-GGG 40.74 12.23 1 1 74.28 - - 
Pic-GGA 42.72 12.78 2 2 76.26* 78.07 - 
 
It is important to note the realization of the unique utilities of affinity-based preparation 
step when the number of samples is further increased. First is the sample complexity reduction. 
While peptide derivatization results to increased chemical complexity, the antibody reagent 
maximally removes interfering chemicals (e.g., large molar excess of reagents) from the 
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derivatization mixtures. The chemical interference deleterious to MS analysis compromises the 
limit of quantitation for derivatization-based quantitative proteomics. Moreover, derivatized non-
target peptides are also removed in the uMRM workflow, similar to affinity-based MRM MS. 
Secondly, enrichment of targeted peptides, compensate for the analyte dilution caused by pooling 
multiple samples. The uMRM workflow pools N numbers of samples together for a single MS 
experiment, which in turn results in N-times dilution of peptide targets. For instance, when the 
samples were combined in the 15-in-1 uMRM MS analysis, analytes in each sample were 
subsequently diluted by 15 times. The original sample volume ranged from 67 to 4000 μL, 
constituting a total volume of about 15 mL. Using a single step of affinity preparation, the 
derivatized SVI and SVI* were reconstituted in a final volume of 10 μL; therefore, the 
concentration of endogenous SVI for each sample was increased by 6.7 to 400 times. 
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Chapter 4. Ultrathroughput mass spectrometry for global quantitative proteomic profiling 
through 18O-labeling in combination with peptide derivatization 
 
4.1. Introduction 
 
The accomplishment of Human Genome Project (HGP) provided the foundation to which 
the full complexity of the human proteome will be established. The characterized genome map, 
along with available transcriptome and proteomic databases, expedited proteomic efforts for 
disease expression profiling.1-3  In 2008, the Human Proteome Organization (HUPO) launched 
the Human Proteome Project (HPP) to systematically map the human proteome. Currently, a 
major component of HPP, chromosome-centric HPP (C-HPP), is in progress. It was aimed to 
provide information on “missing proteins” (proteins that lack MS data or antibody detection). C-
HPP is being complemented by biology- and disease-driven HPP (B/D-HPP), utilizing combined 
resources of worldwide proteomics community.1,2  
 
In light of the clinical relevance of human proteomic research, proteomic technologies for 
clinical aspects such as disease pathogenesis, drug and vaccine development, and biomarker 
discovery can be obtained from serum proteomic profiles.3-5 In particular, the identification of 
disease biomarkers in serum rely on powerful instrumentation and accurate bioanalytical 
methodologies. The following, however, are the major challenges encountered  in serum 
proteomics: (1) pre-analytical issues including collection, storage, and sample processing, (2) 
sample complexity due to large dynamic range of protein concentration, (3) high-abundance 
proteins in serum, (4) high levels of salts and potentially interfering compounds, (5) biological 
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variations, (6) poor reproducibility, (7) clinical trial design pitfalls, and (8) technical limitations. 
Key mass spectrometry technological advancements on different analytical perspectives are 
recently developed to alleviate these limitations.4,6 
 
Results from global quantitative proteomic profiling studies can provide important 
information on the changes within disease-associated proteins. For instance, control and diseased 
plasma sample can be processed (including labeling, digestion, fractionation, and trypsin 
digestion) and analyzed for liquid chromatography (LC) tandem mass spectrometry (MS). From 
tandem MS data, the proteins are identified through database search. The tandem MS mode 
analysis used in identifying proteins is called data-dependent acquisition (DDA), where full MS 
scan is performed, followed by tandem MS acquisitions for each detected analytes. From 
profiling data, differential proteins associated with the disease can be identified, and ultimately 
quantified and benchmarked for further studies.7 Such application of shotgun proteomics for 
identifying and profiling proteins in biological samples has presented significant advances in 
clinically relevant studies. The serum (more broadly as plasma) proteome, which represents 
protein expression of a large number of cell types, contains critical pathophysiological 
information including tissue leakages that could serve as biomarkers.  
 
To enable quantitation, stable isotope-labeled peptides (13C- and 15N) are typically added 
in known amount as spiked-in quantitation reference. Light and heavy peptides are then 
monitored and their ratios obtained to determine the amount of the endogenous peptide. 
However, when quantitation is intended for the entire proteomic profile, a simple and cost-
effective approach is essential. The method of 18O-labeling has proved to be an efficient means 
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to generate a global reference standard out of actual biological sample digests. Global 
quantitative proteomic profiling through 18O-labeling combined with tandem MS analysis have 
been reported.8-10 As MRM-based targeted quantitation of disease-associated proteins in 
biological samples 11-13 are developed, application of the global labeling method coupled to 
MRM MS in discovery and verification of candidate biomarkers also demonstrated the utility of 
the strategy for large-scale multiplexing.14,15 Recent MRM improvement strategies for optimized 
depth and coverage for low concentration proteins (low ng/mL)16, as well as expedited 
workflows through automation of transition selection and optimal MS collision energy (CE) 
prediction.17,18  
  
4.2. Proteomic profiling and uMRM quantitative analysis 
 
4.2.1. Experimental 
 
4.2.1.1 Research facilities 
 
All sample preparations were performed in a Biosafety Level 2 laboratory within the 
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). The HPLC-
UV system (Shimadzu) used for the peptidyl reagent purification is located in R409. LC-TOF-
MS will be performed using 10ADvp system (Shimadzu) and quadrupole time-of-flight (QTOF) 
mass spectrometer (QSTAR Elite, Applied Biosystems). LC-MRM-MS analysis was performed 
using the 10ADvp system described above and 4000 QTRAP triple quadrupole mass 
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spectrometer (Applied Biosystems). The mass spectrometers are in the MS facility of the 
Department of Chemistry (R403). 
 
4.2.1.2. Materials and reagents 
 
Methanol (MeOH), dimethylacetamide (DMAc), LC-MS grade acetonitrile (ACN), urea, 
iodoacetamide (IAA), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMTMM), N-Methylmorpholine (NMM), 1,4-Dimethylpiperazine (DMPipZ), anhydrous 
acetonitrile, phenylmethylsulfonyl fluoride (PMSF), triethylammonium bicarbonate buffer 
(TEAB), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, 
MO). Trifluoroacetic acid (TFA), formic acid (FA), DL-Dithiothreitol (DTT), and AB 
Biosystems Poroszyme immobilized trypsin bulk media were purchased from Fisher (Pittsburgh, 
PA). Female serum was from BioChemed (Winchester, VA). Sequence-grade trypsin was 
purchased from Roche (Indianapolis, IN). Albumin and IgG depletion spin trap was from GE 
Healthcare, (Westborough, MA). H2
18O >97% was purchased from Cambridge Isotope 
Laboratories (Tewksbury, MA). 
 
Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized (DI) water. 
Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven (Fisher 
Scientific, Pittsburgh, PA) or lyophilizer (Labconco, Kansas City, MO). Incubation of samples 
was performed on Thermomixer R (Eppendorf, Hauppauge, NY).   
 
 
85 
 
4.2.1.3. Tryptic digestion and derivatization of serum samples  
 
To 100 μg of sample (pure serum) , 8M urea in 100 mM NH4OAc pH 8.0 buffer (100 μL) 
was added and the tube was vortexed for 30 sec. Additional 100 μL of NH4OAc pH 8.0 buffer 
was added to dilute the sample. Reduction was carried out by adding 4 μL of 500 mM DTE for 
30 min at 30°C and let to cool down, followed by alkylation with 15 μL of 500 mM IAA for 30 
min at RT in the dark. Further dilution with NH4OAc pH 8.0 buffer to a total urea concentration 
of 2 M was performed prior to digestion. Trypsin was added to the sample, with an enzyme-
substrate ratio of 1:25. The sample was incubated overnight at 37°C. To quench the reaction, 
10% TFA was added (total TFA concentration of 2%, v/v) and incubated for 10 min. The 
resulting digests were subsequently desalted using Oasis HLB material (Section 3.2.1.4), 
lyophilized, and stored at -20°C. Sample-specific derivatization of digests follows same protocol 
as Section 3.2.1.4.  
 
4.2.1.4. Preparation of 18O-labeled global internal standard 
 
Tryptic digest of 50 µL depleted serum (using depletion column as per manufacturer’s 
procedure) was desalted and lyophilized. Meanwhile, 100 µL of Tris-Cl was freeze-dried and 
lyophilized. About 4 mg of immobilized trypsin was weighed and washed with 5 volumes of 
water three times. To the digest, 50 µL of anhydrous ACN was added and dried in the Speed 
Vac. The drying procedure was repeated for a total of three times. The lyophilized Tris-Cl buffer 
was reconstituted with 100 µL of H2
18O, producing the 18O-buffer. To the desalted digest, 20 µL 
of anhydrous acetonitrile was added to dissolve the sample, followed by the addition of 30 µL of 
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18O-buffer. The sample incubated for 10 min at room temperature (without shaking or 
vortexing). Additional 50 µL of 18O-buffer was added, and the sample was incubated for another 
10 min. All 100 µL solution was transferred to a microcentrifuge tube containing previously 
washed immobilized trypsin and incubated overnight at 37°C. After taking out from the 
thermomixer, 100 µL of anhydrous ACN was added to the sample. The labeled peptides are 
recovered in the supernatant following a 2 min microcentrifugation at room temperature. 
 
4.2.2. Results and discussion 
 
4.2.2.1. Monitoring mid-concentration proteins and the effect of peptide derivatization 
 
The sample complexity and high dynamic range of plasma protein concentrations, 
however, limit the adaption of standard chromatographic workflows in proteomic analysis 
Peptide derivatization using peptidyl reagents offers signal enhancement for increased analytical 
detectability in MS. In this study, peptide derivatization was performed to improve peptide signal 
for proteomic profiling of human serum samples. To take advantage of the inherent signal 
enhancement from derivatization data, standard flow 1D LC-MS/MS was used to evaluate the 
preliminary proteomic profile. 
 
Analysis using DDA MS of derivatized and nonderivatized tryptic serum digests 
generated spectral data sets, which were then used for searching against human protein 
databases. Profiles of identified mid- to high-abundance serum proteins using the developed 
methods are then compared to the results from underivatized samples. Database search was 
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performed in Peaks and Mascot search engine software against most recent human protein 
database obtained from Uniprot. The number of proteins identified, however, was low (at most 
130), which can be attributed to the use of standard LC and ESI source. Albeit the low number of 
identified proteins, the search produced peptide-to-spectrum matches corresponding to 
derivatized peptides. Peptidyl reagents Pr-ALG, Pr-GFG, and Pic-GGG were used for 
derivatization. The identified proteins are then evaluated and quantified through a global 
proteome reference. The schematic for the selection of proteins of interest from profiling data is 
shown in Figure 4.1. 
 
 
Figure 4.1. Selection of proteins from serum profiling preliminary results. 
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4.2.2.2. Stability study for 18O-labeled global internal standard for global quantitative 
applications 
 
Various proteolytic enzymes, such as Lys-C, chymotrypsin, and Glu-C, can be used for 
the enzyme-catalyzed double 18O incorporation, provided that the same enzyme was used for 
digestion. The sample must be digested in highly enriched (>95%) H2
18O to attain complete 
double incorporation. Scheme 2 shows the mechanism for enzyme-catalyzed labeling of the 
peptide. The enzyme bonds to the target residue covalently, followed by reaction with H2
18O 
within the C-terminal. The incorporation of the second 18O-label occurs when the enzyme 
rebinds the C-terminal residue.  
 
 
Scheme 2. Enzyme-catalyzed incorporation of two 18O with digestion and labeling in a single 
step. 
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Comparative proteomics application of the labeling technique allows for characterization 
of various states at which a protein exists. A sample spectrum where the isotopic distribution 
corresponds to unlabeled 16O and labeled 18O peptides is shown in Figure 4.2. A sample of 1:1 
mixture of 16O- and 18O-labeled digest, the peak intensities I0, I2, and I4 and masses M0, M2, and 
M4 are used to calculate the corrected ratio for comparative analysis.  
 
 
 
Figure 4.2. Pair of double-charged peptides from a 1:1 mixture of 16O- and 18O-labeled digest, 
showing 4 Da difference from two 18O atoms incorporated. (Adapted from Castillo, et al, a 
protocol update for earlier work from University of Maryland).19 
 
The proteolytic digestion in the first steps of digestion is solution phase, where the excess 
amount of enzyme added should be inactivated or removed to prevent back-exchange. Back-
exchange of the oxygen labels is correlated with residual enzyme, and is an issue during storage 
and sample preparations. Use of immobilized enzyme during labeling enables efficient removal 
of residual in-solution enzyme. A protocol update to investigate the stability of labeled peptides, 
Expected Observed 
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and thereby the effect of residual trypsin, was performed in a separate experiment.19 The stability 
of oxygen labels was investigated by storing the 18O2-labeled peptide solutions at 4°C under four 
conditions for 7 days: (1) 0.2% FA, (2) 0.2% FA with 2 μM PMSF, a serine protease inhibitor, 
(3) 20 mM TEAB, and (4) 20 mM TEAB with 5 μM PMSF. No measureable increases in the 
signals for peptides with the single and zero 18O labels were observed for all conditions. Effect of 
PMSF is not evident, which is attributed to efficient inactivation or removal of solution-phase 
trypsin. Figure 4.3 shows MS spectra of a monitored peptide from buffer-stored digest sample. 
BSA tryptic peptide doubly-charged LVNELTEFAK in 20 mM TEAB  In Figure 4.4, no 
apparent significant change was observed on the 18O/16O calculated ratios for the time course 
stability investigation. 
 
 
Figure 4.3. TOF-MS spectra of an 18O-labeled BSA tryptic peptide at Day 0 and Day 7. 
 
 
Day 0 
Day 7 
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Figure 4.4. Calculated 18O/16O for time-course stability study to monitor back-exchange at 
varied conditions. 
 
Stability was recently further verified by performing a peptide level affinity pull down of 
labeled standard peptide SVILLGR-[18O2],  which implicates its further potential for use in 
targeted quantitative proteomics. 
 
4.2.2.3. Back to multiplexing: Deriving the N-in-1 sample throughput to analyte throughput 
for global quantitative proteomics application 
 
Proteolytic 18O-labeling is a global, flexible, and robust technique for comparative 
proteomics. A global reference internal standard was prepared out from half of the serum digest. 
Proteins identified from post-derivatization samples were monitored in standard LC MRM MS.  
Table 4.1 lists the selected peptides and the endogenous to internal standard ratios obtained. A 
number of peptides yielded ratios close to 1, deeming them as putative surrogate peptides for 
quantitation. Also shown are the concentrations of the corresponding protein from literature. 
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Increasing the coverage and reducing the sample complexity are essential for a global 
quantitative approach. An initiated study on combining uMRM and cysteinyl peptide enrichment 
wherein reduction of sample complexity is made possible via biotinylation and avidin size-
exclusion filtration, will enable such analysis. A recently developed technique, called CysTRAQ 
integrates iTRAQ and enrichment of cysteinyl peptides for uncovering and quantifying hidden 
proteomes.20 Contrasting with the N-in-1 uMRM MS workflow previously shown in Figure 3.1, 
Figure 4.5 presents the transformed analytical technique for analyzing a number of selected 
proteins in multiple serum samples. Realization of the combined will be beneficial in the early 
stage analysis within the biomarker pipeline without the need for antibodies. In addition, 
replicate experiments in one analysis can be performed through peptide derivatizations. 
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Table 4.1. Comparative quantitation investigation of monitored peptides from serum proteome 
using 18O-labeled global reference standard. 
Protein Peptide 
Conc. From 
Literature 
(ng/mL)12 
Ratio 
(Endogenous/IS) 
Alpha-1-antitrypsin ITPNLAEFAFSLYR No data ND 
 
LQHLENELTHDIITK No data 1.75 
 
LSITGTYDLK 6.1E+06 ND 
 
SVLGQLGITK 1.1E+06 1.31 
 
VFSNGADLSGVTEEAPLK 3.6E+05 1.18 
Clusterin ELDESLQVAER 2.0E+05 1.01 
Haptoglobin DIAPTLTLYVGK 4.6E+05 0.51 
 
HYEGSTVPEK 1.3E+05 0.47 
 
VGYVSGWGR 1.3E+06 3.46 
Alpha-1-acid 
glycoprotein 1 
NWGLSVYADKPETTK 1.8E+02 1.18 
Pregnancy zone protein ISEITNIVSK 7.3E+03 ND 
Beta-2-glycoprotein 1 ATVVYQGER 2.1E+05 ND 
Histidine-rich 
glycoprotein 
ADLFYDVEALDLESPK 1.8E+06 0.96 
 
DGYLFQLLR 7.0E+04 ND 
 
GGEGTGYFVDFSVR 1.0E+06 1.08 
Apolipoprotein A-I ATEHLSTLSEK 1.0E+06 1.58 
 
DLATVYVDVLK 8.7E+05 1.26 
 
VQPYLDDFQK 2.3E+05 0.80 
 
VSFLSALEEYTK 9.7E+04 1.41 
Hemopexin NFPSPVDAAFR 4.0E+05 0.84 
Ceruloplasmin DIFTGLIGPMK 2.0E+01 1.85 
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Figure 4.5. Cysteinyl peptide enrichment workflow. 
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Chapter 5. Conclusions and perspectives 
 
With sample-specific, non-isotopic derivatization of digests of human biological samples, 
ultrathroughput mass spectrometry (uMS) was developed for targeted quantitative proteomics. 
Intrinsic analyte multiplexing capability of mass spectrometry was leveraged to achieve sample 
multiplexing that will break through the sample-throughput bottleneck of current mass 
spectrometry methods. The novel bioanalytical platform integrates non-isotopic peptide 
derivatization, single peptide-level enrichment technique, and MRM MS analysis to perform N-
in-1 quantitation of signature peptides from low-abundant proteins. Peptidyl reagents were 
prepared for uMS screening to identify reagents that enable high signal yield in mass 
spectrometry. Using these reagents for sample-specific derivatizations, one-experiment 
quantitation of multiple serum samples containing common, low-abundance prostate specific 
antigen was demonstrated.  
 
The open-source design of uMRM MS technology offers facile adaptability for 
improving the sample throughput in protein biomarker validation and the flexibility of the assay 
across different candidates. A repository of peptidyl reagents with high signal enhancement 
capabilities was obtained from screening of more than a thousand of reagents. The novel 
bioanalytical platform presented minimum utilization of isotope labels and does not require 
immunograde antibodies, unlike current immunoassay validation gold standards. Moreover, 
sample complexity and dilution issues are mitigated by the peptide-level affinity-based 
preparation, enabling the elimination of preliminary depletion of high-abundance serum proteins 
in the upstream sample processing.  
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With the signal-enhancing advantages, analyte throughput, and enrichment capabilities, 
uMRM has the potential to further present an interesting application: to analyze protein 
biomarker panels in multiple samples. This integration of multiplexing and sample throughput 
dimensions, a current undertaking in the laboratory, will provide multiplexed N-in-1 approach 
that will further expand the utility of uMS approach in the biomarker development. 
 
The peptide-specific signal enhancement properties of the derivatization were further 
exploited for global quantitative proteomics application. A proof-of-concept study analyzed 
human serum proteins with standard flow LC-MS instrumentation. A universal reference serum 
proteome standard was prepared for the analysis using 18O labeling.  These studies will then help 
commence the advancement of the technology for measuring biomarker candidates in larger 
number of clinical serum samples. Future work on this novel technology can also be directed 
towards the evaluation of candidate protein biomarkers across different forms of cancer and 
other complex diseases, and find important implementation in clinical cancer researches. 
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Appendix 
Appendix 1: MS Screening data for peptide CFTR01 derivatization with library of peptidyl 
reagents 
  
LC-TOF-MS Analysis, Peak Height 
Peptidyl Reagent 
CFTR01 
SYMS, % 
N-terminal 
modification  
Short 
peptide 
sequence 
1 Dim βAVF 4.4E+02 
2 Dim LAA 2.9E+02 
3 Dim LVL 2.1E+02 
4 Dim LAL 2.4E+02 
5 Dim LVG 6.4E+02 
6 Dim LAG 5.4E+02 
7 Dim LVF 2.1E+02 
8 Dim LAF 2.8E+02 
9 Dim LAV 4.4E+02 
10 Dim FAV 1.3E+02 
11 Dim FAA 1.7E+02 
12 Dim FAL 1.5E+02 
13 Dim FAG 1.2E+02 
14 Dim FAF 4.1E+02 
15 Dim FLG 1.6E+02 
16 Dim FVL 1.4E+02 
17 Dim VLF 1.2E+02 
18 Dim VFV 1.7E+02 
19 Dim LLF 1.1E+02 
20 Dim LFF 1.4E+02 
21 Dim LFV 2.3E+02 
 
  
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
CFTR01 
SYMS, % 
N-terminal 
modification  
Short 
peptide 
sequence 
1 Dim LFA 7.5E+02 
2 Dim LGA 1.2E+03 
3 Dim FGV 1.4E+02 
4 Dim FLV 1.5E+03 
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(Cont’d.)  
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
CFTR01 
SYMS, % 
N-terminal 
modification  
Short 
peptide 
sequence 
5 Dim FFA 1.1E+04 
6 Dim FLA 8.9E+02 
7 Dim FLL 3.6E+02 
8 Dim FLF 3.5E+02 
9 Dim VGV 1.4E+02 
10 Dim VLV 1.7E+02 
11 Dim VFA 1.1E+03 
12 Dim VGA 6.7E+02 
13 Dim VLA 8.7E+02 
14 Dim VGG 9.6E+02 
15 Dim VLG 9.7E+02 
16 Dim VFF 5.7E+02 
17 Dim AFV 4.6E+02 
18 Dim AGF 4.7E+02 
19 Dim AGG 1.8E+02 
20 Dim ALG 2.3E+02 
21 Pr AFA 1.2E+03 
22 Pr AGA 6.9E+02 
23 Pr ALA 5.0E+02 
24 Pr AFG 5.0E+02 
25 Pr ALG 1.3E+02 
26 Pr AFF 3.1E+02 
27 Pr AGF 7.8E+02 
28 Pr ALF 4.2E+02 
29 Pr VFA 1.2E+03 
30 Pr VGA 1.1E+03 
31 Pr VLA 1.1E+03 
32 Pr VGG 2.5E+02 
33 Pr VLG 3.5E+02 
34 Pr FGV 1.7E+02 
35 Pr FGA 2.1E+03 
36 Pr FLA 1.0E+03 
37 Pr FGG 2.8E+02 
38 Pr FGF 1.8E+03 
39 Gl FFA 8.8E+02 
40 Gl FGA 1.1E+03 
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(Cont’d.)  
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
CFTR01 
SYMS, % 
N-terminal 
modification  
Short 
peptide 
sequence 
41 Gl FLA 3.7E+02 
42 Gl FGG 2.1E+02 
43 Gl FFF 4.1E+02 
44 OPA VFA 2.9E+02 
45 OPA VGA 2.0E+02 
46 OPA VLA 3.1E+02 
47 OPA VFF 1.7E+02 
48 OPA VLF 1.9E+02 
49 Pic GFA 2.6E+02 
50 Pic GGA 7.4E+02 
51 Pic GLA 2.0E+02 
52 Pic GFG 1.6E+02 
53 Pic GGG 5.6E+02 
54 Pic GLG 2.7E+02 
55 Pic GGF 3.5E+02 
56 Pic GLF 1.4E+02 
57 Dim VAGL 4.0E+02 
58 Dim VAGF 6.2E+02 
59 Dim VGAG 4.1E+02 
60 Dim VGVL 5.0E+02 
61 Dim VGVF 8.3E+02 
62 Dim VGVG 4.6E+02 
63 Dim VGVV 3.5E+02 
64 Dim VGAA 5.5E+02 
65 Dim VGVA 8.5E+02 
66 Dim GAAL 2.6E+02 
67 Dim GAAF 4.8E+02 
68 Dim GAVL 1.5E+02 
69 Dim GAVF 2.8E+02 
70 Dim GAVV 4.2E+02 
71 Dim GAAA 3.2E+02 
72 Dim GAVA 5.5E+02 
73 Dim AFAL 8.8E+02 
74 Dim AFAF 1.4E+03 
75 Dim AFAG 5.5E+02 
76 Dim AFVL 9.1E+02 
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(Cont’d.)  
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
CFTR01 
SYMS, % 
N-terminal 
modification  
Short 
peptide 
sequence 
77 Dim AFVF 1.3E+03 
78 Dim AFVG 4.7E+02 
79 Dim AFVV 1.8E+02 
80 Dim AFAA 1.6E+03 
81 Dim AFVA 1.3E+03 
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Appendix 2: MS Screening data for peptide SVI derivatization with library of peptidyl reagents 
 
 
LC-TOF-MS Analysis, Peak Height 
Peptidyl Reagent 
SVI SYMS, 
% 
N-terminal 
modification  
Short peptide 
sequence 
1 Pr GFV 5.7E+02 
2 Pr GGV 1.4E+02 
3 Pr GLV 2.8E+03 
4 Pr GFA 5.3E+03 
5 Pr GLF 3.0E+02 
6 Pr LGV 1.4E+02 
7 Pr LFA 1.0E+02 
8 Pr LGA 8.8E+02 
9 Pr LLA 1.9E+02 
10 Pr LFG 1.8E+02 
11 Pr LGG 4.0E+02 
12 Pr LLG 1.6E+02 
13 Pr LLV 1.8E+02 
14 Pr VFA 3.0E+02 
15 Pr VGA 5.1E+02 
16 Pr VLA 2.4E+02 
17 Pr VFG 2.0E+02 
18 Pr VGG 3.0E+02 
19 Pr VLG 2.2E+02 
20 Pr VGF 2.0E+02 
21 Pr AFA 4.8E+02 
22 Pr AGA 1.1E+03 
23 Pr ALA 5.7E+02 
24 Pr AFG 3.5E+02 
25 Pr AGG 2.5E+02 
26 Pr ALG 2.8E+02 
27 Pr AGF 3.5E+02 
28 Pr GGA 4.8E+03 
29 Pr GLA 2.5E+03 
30 Pr GFG 8.7E+02 
31 Pr GGG 1.8E+03 
32 Pr GLG 1.1E+02 
33 Pr GFF 2.5E+03 
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(Cont’d.)  
LC-TOF-MS Analysis, Peak Height 
Peptidyl Reagent 
SVI SYMS, 
% 
N-terminal 
modification  
Short peptide 
sequence 
34 Pr GGF 3.0E+02 
35 Pic GGA 8.5E+02 
36 Pic GFG 3.3E+02 
37 Pic GGG 1.2E+03 
38 Pic GLG 3.9E+02 
39 Pic GGF 3.0E+02 
40 Dim FVVF 1.1E+02 
41 Dim FVAV 3.4E+03 
42 Dim FVVA 2.6E+03 
 
  
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
SVI SYMS, 
% 
N-terminal 
modification  
Short peptide 
sequence 
1 Dim AVA 2.8E+02 
2 Dim AVG 6.4E+02 
3 Dim AAV 4.1E+02 
4 Dim AAA 1.9E+02 
5 Dim AAG 5.4E+02 
6 Dim VVG 1.7E+03 
7 Dim VAV 7.0E+02 
8 Dim VAA 1.0E+03 
9 Dim VAL 3.0E+02 
10 Dim VAG 1.4E+03 
11 Dim VAF 5.3E+02 
12 Dim GVA 4.6E+02 
13 Dim GVG 6.3E+02 
14 Dim GVF 2.2E+02 
15 Dim GAV 7.0E+02 
16 Dim GAA 4.0E+02 
17 Dim GAL 1.3E+02 
18 Dim GAG 1.0E+03 
19 Dim GAF 5.0E+02 
20 Dim LFG 1.5E+03 
21 Dim LVG 1.4E+03 
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(Cont’d.)   
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
SVI SYMS, % N-terminal 
modification  
Short 
peptide 
sequence 
22 Dim GLL 1.1E+03 
23 Dim GLG 1.7E+02 
24 Dim GFL 1.1E+03 
25 Dim GFG 1.8E+02 
26 Dim GVL 6.3E+02 
27 Dim FVAF 2.3E+03 
28 Dim FVAL 1.2E+03 
29 Dim FVVL 8.0E+02 
30 Dim FVVG 8.6E+02 
31 Dim FVAA 3.9E+03 
32 Dim GLVV 3.0E+03 
33 Dim GLAA 2.8E+03 
34 Dim GVVV 2.7E+02 
35 Dim βAAVG 2.1E+03 
36 Dim βAVAF 2.6E+03 
37 Dim bAL 1.1E+03 
38 Dim bAG 8.4E+02 
39 Dim bAA 3.8E+02 
40 Pr LLV 1.4E+02 
41 Pr FVAA 1.1E+02 
42 Pr FVVL 2.0E+02 
43 Pr AFVG 7.0E+02 
44 Pr AFAG 3.6E+02 
45 Pr AFAF 1.2E+02 
46 Pr AFAL 1.4E+02 
47 Pr GLGG 1.0E+03 
48 Pr GLLL 4.9E+02 
49 Pr GLFF 4.7E+02 
50 Pr GVFF 3.5E+02 
51 Pr GLAA 2.2E+03 
52 Pr VLGG 1.2E+03 
53 Pr VLAA 8.3E+02 
54 Pr LLGG 7.2E+02 
55 Pr LVGG 3.9E+02 
56 Pr LVAA 6.4E+02 
57 Pr ALVV 7.4E+02 
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 (Cont’d.)  
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
SVI SYMS, % N-terminal 
modification  
Short 
peptide 
sequence 
58 Pr FAFV 1.5E+02 
59 Pr FALV 4.8E+02 
60 Pr FAGF 3.4E+02 
61 Pr AGVG 1.4E+02 
62 Pr GLAG 2.0E+02 
63 Pr GLFG 2.6E+02 
64 Pr GAVV 9.5E+02 
65 Pic AFVA 2.7E+02 
66 Pic AFAA 5.5E+02 
67 Pic AFVV 2.6E+02 
68 Pic AFVG 3.8E+02 
69 Pic AFAG 4.4E+02 
70 Pic AFAL 1.5E+02 
71 Pic AFAF 1.1E+02 
72 Pic VGAA 9.0E+02 
73 Pic VGAF 5.2E+02 
74 Pic VGVG 1.7E+03 
75 Pic VGAG 3.3E+02 
76 Pic GLGG 1.7E+03 
77 Pic GLFF 1.3E+02 
78 Pic GVGG 3.9E+02 
79 Pic GVFF 1.6E+02 
80 Pic LLGG 1.4E+03 
81 Pic LVGG 6.1E+02 
82 Pic VLGG 2.7E+03 
83 Pic VVAA 3.6E+02 
84 Pic VVGG 7.9E+02 
85 Pic VLAA 1.9E+02 
86 DEABA GGG 1.1E+02 
87 DEABA GLG 1.8E+02 
88 Gl AFVL 1.6E+03 
89 Gl AFVF 1.2E+03 
90 Gl AFVG 2.9E+02 
91 Gl AFAV 1.7E+03 
92 Gl GAAL 3.7E+02 
93 Gl GAAG 3.1E+02 
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 (Cont’d.)  
NanoLC-MRM-MS Analysis, Peak Area 
Peptidyl Reagent 
SVI SYMS, % N-terminal 
modification  
Short 
peptide 
sequence 
94 Ac FVG 5.9E+02 
95 Ac FFG 2.8E+02 
96 Ac FLG 2.4E+02 
97 Ac FLL 1.1E+02 
98 Ac VVV 1.7E+02 
99 Ac VLV 1.4E+02 
100 Ac βAVL 1.1E+03 
101 Ac βAVF 3.4E+02 
102 Ac βAGL 4.8E+02 
103 Ac βAGF 1.1E+02 
 
 
 
 
 
 
 
 
 
 
